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Abstract
The combined application of the novel, clinically relevant microtubule stabilizing agent 
(MTSA) patupilone and ionizing radiation (IR) is a very promising treatment modality in 
cancer therapy as previously investigated at a preclinical level in our laboratory. Patupilone 
(epothilone B) is a compound of bacterial origin, which binds to the same site on beta-tubulin 
as taxanes, but has number of advantages over the later, e.g. potent cytotoxicity in multi-drug 
resistant tumors and – due to its relatively simple chemical structure – the availability of 
derivatives with improved pharmacological properties. Patupilone has a strong supra-additive 
inhibitory effect on the growth of tumor xenografts in mice when applied together with IR. 
Interestingly, the additive cytotoxic effect was much less pronounced in vitro indicating that 
an additional effect on the level of tumor microenvironment must exist. While the initial 
hypothesis was that patupilone targets neovascular endothelial cells directly, further investi-
gations revealed that the additive effect in vivo could only be observed in tumors xenografts 
derived from patupilone sensitive cancer cells. Thus the effect on the tumor microenviron-
ment might be induced in an indirect way, mediated by tumor cells, for example via the 
secretion of biologically active molecules. 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with a broad 
variety of substrates including components of the extracellular matrix and growth factors (e.g. 
the transforming growth factor β (TGF- β). MMPs play an important role in the regulation 
of cell survival, apoptosis, angiogenesis, matrix remodelling and metastasis. The function 
of MMPs is strictly regulated by a complex activation processes (MMPs are expressed as 
zymogens) and natural inhibitors of their enzymatic activity. The tissue inhibitors of MMPs 
(TIMPs) represent a group of the most important players in the MMP regulation cascade cur-
rently known. TIMPs are a family of small proteins (size of 20-30 kDa), that contains 4 
members: TIMP-1-4. All 4 TIMPs are potent inhibitors of the MMP enzymatic activity; TIMP-2 
was also shown to be a co-activator of MMP-2 zymogen. Additionally, TIMPs have MMP 
independent biological functions, for example mitogenic, pro- and anti-apoptotic.  MMPs and 
TIMPs are secreted both by tumor-associated stromal cells and by cancer cells and are impor-
tant components of the tumor microenvironment. Overexpression of MMPs and TIMPs was 
reported for almost all tumor types and associated with a bad survival prognosis. 
In the present study we focused our investigations on the effect of the microtubule sta-
bilizing agent patupilone on the MMP function in tumor cells after treatment with ionizing 
radiation. The results presented herein further confirmed the radiosensitizing capacity of patu-
pilone to enhance IR-induced cytotoxicity in a wide range of human cancer cells (HCT116 
colon carcinoma cells, HT1080 fibrosarcoma cells, U251 glioma cell and medulloblastoma 
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cell lines DAOY, D425, D341). It is also interesting to note that patupilone sensitized 
to ionizing radiation already in a very low dose range. At these doses patupilone was not 
cytotoxic itself and did not alter microtubule cytoskeletal structures (0.2 nM patupilone in 
HT1080 cells). The combined treatment modality with patupilone and IR is more potent in 
vivo than in cellular model systems. Most probably, this is due to the additional treatment 
effects on the level of the tumor microenvironment, which may be mediated by tumor cells. 
Herein, we investigated an effect of the indicated treatment regimens on one of the important 
components of the tumor microenvironment, namely MMPs. We identified that the activity of 
secreted MMP was upregulated after treatment with IR and that pre-treatment with patupilone 
could diminish this increase. MMP activity is required for tumor cell invasion as well as for 
other cellular processes. In this study tumor cell invasiveness was indeed increased after IR 
and, in line with the events on the level of MMP activity, patupilone could counteract this 
effect of IR.
In an attempt to uncover mechanisms that contribute to the counteracting effect of 
patupilone on IR-induced MMP activity, we dissected the MMP regulation cascade on vaious 
levels. Patupilone did not influence IR-induced events on the level of cell cycle distribution 
and gene transcription. Namely, patupilone did not interfere with the accumulation of cells in 
G2/M phase after IR and did not alter IR-induced transcription of MMPs and TIMPs. Both 
MMP and TIMP protein levels were elevated in the cell lysate and conditioned cell 
culture media (CM) after treatment with 10 Gy of IR. Patupilone did not influence intracellu-
lar and extracellular protein levels of MMPs. However, the amount of extracellular TIMP-1 and 
TIMP-2 proteins after combined treatment with patupilone and IR was significantly reduced 
when compared to treatment with IR alone. Furthermore, the counteracting effect of patupi-
lone on IR-induced MMP activity was not observed in TIMP-1 and TIMP-2 depleted cells. 
After TIMP depletion the IR-increased MMP activity did not exceed the MMP activity level 
after combined treatment in non-depleted cells, indicating that the proMMP activation 
processes after IR requires TIMPs. These findings strongly suggest that patupilone coun-
teracted IR-induced MMP activity due to the interference with the MMP activation processes 
by the depletion the secreted TIMP-1 and TIMP-2 proteins.
To our knowledge, we demonstrate for the first time that patupilone can counteract IR-
induced MMP-related processes. It is particularly interesting is that the counteracting effect 
of patupilone was observed in human glioma cells. Glioblastoma (or grade IV glioma) is 
one of the most treatment resistant tumors in adults. The primary reasons associated with the 
poor prognosis are: extensive infiltration of surrounding brain tissue by tumor cells and the 
blood-brain barrier as an obstacle for the adequate delivery of chemotherapeutics. The ability 
of patupilone to cross the blood-brain barrier makes patupilone a very potent and promising 
chemotherapeutical agent for the treatment of brain malignancies. The capacity of patupilone 
to inhibit IR-induced glioma cell invasion, as shown in the present study, increases the value 
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of the compound as a candidate for a combination with radiation therapy for glioblastoma 
treatment.
MMPs play an important role in cancer progression by remodelling the extracellular 
matrix and regulating multiple biologically active molecules. Overexpression of MMPs and 
TIMPs in multiple tumor types positively correlates with the aggressiveness of the disease. 
There is a strong indication that radiation therapy can promote MMP expression and tumor 
invasiveness. Thus, therapeutic agents that cleverly target members of MMP and TIMP 
families in selective and disease/function-specific way can represent an interesting class of 
agents for a combination with ionizing radiation.
This study demonstrates that the MTSA patupilone is a compound of great interest. It is 
a potent inhibitor of tumor cell proliferation under hypoxic and normoxic conditions, a very 
promising anti-metastatic and anti-angiogenic agent, a potent radiosensitizer in vivo and in 
vitro (as described elsewhere). In addition, the present study demonstrated that patupilone 
inhibits IR-induced activity of secreted MMPs and IR-induced cell invasion. Since IR-in-
duced MMP activity may be relevant to cancer progression, the combined treatment modality 
of IR and patupilone might, indeed, be of great clinical benefit for cancer therapy.
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Zusammenfassung
Die Kombinationstherapie von ionisierender Strahlung mit dem neuen, klinisch relevanten 
Microtubuli-stabilisierenden Agens (MSTA) Patupilone ist eine vielversprechende Behand-
lungsmethode gegen Krebs, die in unserem Labor auf präklinischer Ebene untersucht wird. 
Patupilone (Epothilone B), welches aus Bakterien gewonnen wird, bindet an der gleichen 
Stelle an β-tubulin wie Taxane. Im Gegensatz zu Taxanen ist Patupilone aber auch in multi-
drug resistenten Tumoren wirksam und wegen seiner einfachen chemischen Struktur exist-
ieren Derivate mit verbesserten pharmakokinetischen Eigenschaften. Die Kombination von 
Patupilone und ionisierender Strahlung zeigt eine stark supra-additive Hemmung des Tumor-
zellwachstums in Tumor Xenografts in Mäusen. Interessanterweise ist dieser ergänzende Ef-
fekt viel geringer in vitro, was darauf schliessen lässt, dass die gemeinsame Behandlung von 
ionisierender Strahlung mit Patupilone einen zusätzlichen Effekt auf die Tumorumgebung 
ausübt. Zu Beginn wurde davon ausgegangen, dass Patupilone einen direkten Effekt auf neo-
vaskuläre Endothelialzellen hat. Nachdem aber festgestellt wurde, dass dieser additive Effekt 
in vivo nur in Patupilone sensitiven Tumorzellen zu beobachten ist, wird angenommen, dass 
Patupilone einen indirekten Effekt auf die Tumorumgebung ausübt, der über Tumorzellen 
vermittelt wird, z.B. Sekretion von biologisch aktiven Faktoren.
Matrix Metalloproteinasen (MMPs) sind Zink-abhängige Endopeptidasen mit einem bre-
iten Spektrum an Substraten, zu denen Komponenten der extrazellulären Matrix und Wachs-
tumsfaktoren gehören (Transforming growth factor β (TGF-β). MMPs spielen eine wichtige 
Rolle für Zellüberleben, Apoptose, Angiogenese, Matrix Modulierung und in der Metastasen-
bildung. Die MMP-Aktivität ist durch einen komplexen Aktivierungsmechanismus (MMPs 
werden als Zymogene sekretiert) und durch natürliche Inhibitoren reguliert. Die Tissue in-
hibitors of matrix metalloproteases (TIMPs) sind eine Familie von vier kleinen Proteinen 
(20-30kDa). TIMPs sind die wichtigsten MMP-Regulatoren die man bis anhin kennt. Alle 4 
TIMPs inhibieren die enzymatische Aktivität von MMPs. Zudem konnte gezeigt werden, dass 
TIMP-2 in der MMP-2-Zymogen-Aktivierung involviert ist. Zusätzlich zur Regulierung von 
MMP-Aktivität haben TIMPs auch MMP-unabhängige Funktionen, z.B. mitogene, pro- und 
anti-apoptotische Funktionen. MMPs werden von Tumor- und Tumor-assoziierten Stromazellen 
sekretiert und stellen einen wichtigen Bestandteil der Tumorumgebung dar. Überexprimier-
ung von MMPs und TIMPs konnte in fast allen Tumorentitäten festgestellt werden und geht 
mit einer schlechten Überlebensprognose einher.
Im Fokus der vorliegenden Arbeit stand daher die Untersuchung der Wirkung des 
Mikrotubuli stabilisierenden Agens Patupilone auf die MMP-Aktivität in bestrahlten Zel-
len. Die Resultate der Arbeit zeigen, dass Patupilone zu einer erhöhten Zytotoxizität in be-
vstrahlten Zellen führt. Dies wurde schon früher berichtet und konnte hier in verschiedenen 
Zelllinien bestätigt werden (HCT116 Coloncarcinom Zellen, HT1080 Fibrosarcom Zellen, 
U251 Glioma Zellen und in den Medulloblastom Zelllinien DAOY, D425, D341). Von 
spezieller Bedeutung ist die Tatsache, dass Patupilone schon in nicht-zytotoxischen Dosen, 
welche die Mikrotubulistruktur nicht verändern, diesen Effekt zeigt (0.2nM in HT1080). 
Wie schon erwähnt, ist die gemeinsame Behandlung mit Patupilone und ionisierender Strah-
lung wirksamer in vivo als in vitro, weshalb davon ausgegangen wird, dass ein zusätzlicher, 
indirekter Effekt von Tumorzellen auf die Tumorumgebung stattfindet. In dieser Arbeit wurde 
daher der Effekt von Patupilone in Kombination mit ionisierender Strahlung auf MMPs, eine 
wichtige Komponente der Tumorumgebung, untersucht. Wir konnten zeigen, dass Bestrah-
lung zu erhöhter MMP-Aktivität führt und dass die Behandlung mit Patupilone diesen Anstieg 
der MMP-Aktivität hemmt. MMP-Aktivität wird auch für die Zellinvasion benötigt und daher 
wird auch die strahleninduzierte Invasion durch die Behandlung mit Patupilone inhibiert. Um 
mehr über den Mechanismus zu erfahren, durch den Patupilone MMP-Aktivität und Invasion 
inhibieren kann, wurde die MMP-Regulierung auf verschiedenen Ebenen untersucht. 
Es konnte gezeigt werden, dass Patupilone die strahleninduzierten Prozesse nicht durch 
Veränderungen in der Zellzyklusverteilung oder der Gentranskription beeinflusst (Patupilone 
hatte keinen Einfluss auf den strahleninduzierten G2/M Phase Arrest und veränderte auch die 
Transkription von TIMPs und MMPs nicht). Sowohl MMP als auch TIMP Proteinmengen waren 
erhöht in Zelllysaten und in konditioniertem Medium nach Bestrahlung mit 10 Gy. Patupilone 
hatte keinen Einfluss auf die intra- und extrazellulären MMP Proteinmengen. Interessanter-
weise aber waren die extrazellulären Proteinmengen von TIMP-1 und TIMP-2 signifikant 
niedriger in Zellen die kombiniert mit Strahlung und Patupilone behandelt wurden, als in 
Zellen die nur bestrahlt wurden. Des Weiteren konnte gezeigt werden, dass der inhibitorische 
Effekt von Patupilone auf strahleninduzierte MMP-Aktivität in TIMP herunterregulierten 
Zellen nicht mehr beobachtet werden konnte. In Zellen, in welchen TIMP Proteine herun-
terreguliert wurden, war die Aktivierung von MMP nach Bestrahlung in gleichem Ausmass 
inhibiert wie in Zellen, in denen die TIMP Proteine nicht herunterreguliert wurden. Diese 
Daten weisen stark darauf hin, dass strahleninduzierte MMP Aktivierung TIMP abhängig 
ist und dass Patupilone diese strahleninduzierte MMP Aktivierung durch die Reduktion von 
extrazellulärem TIMP-1 und TIMP-2 inhibieren kann.
Nach unserem Wissen sind wir die Ersten die zeigen können, dass Patupilone strahlen-
induzierte Aktivierung von MMPs hemmen kann. Von spezieller Bedeutung ist, dass dieser 
Effekt von Patupilone in menschlichen Gliomazellen gezeigt werden konnte. Glioblastome 
(oder Grad 4 Glioma) gehören zu den resistentesten Tumoren in Erwachsenen. Der Grund 
für die hohe Resistenz ist die starke Infiltrierung von Hirngewebe durch die Tumorzellen 
und die Blut-Hirn-Schranke, welche sich als Barriere für viele Chemotherapeutika erwiesen 
hat. Patupilone aber kann die Blut-Hirn-Schranke passieren. Die Fähigkeit von Patupilone, 
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die Invasivität von Glioblastomen zu hemmen, erhöht das klinische Potential dieses Agens 
zusätzlich und macht es zu einem vielversprechenden Therapeutikum in der Krebsbehand-
lung in Kombination mit Bestrahlung.
MMPs spielen eine wichtige Rolle im Fortschreiten von Krebs durch Veränderung der 
extrazellulären Matrix und multipler bioaktiver Moleküle. Überexprimierung von MMPs und 
TIMPs in verschiedenen Tumorentitäten geht einher mit der Aggressivität der Erkrankung. 
Viele Berichte deuten darauf hin, dass die Strahlentherapie zu einer erhöhten MMP-Aktivität 
führen und die Invasivität von Tumoren fördern kann. Daher könnten Therapeutika, welche 
spezifisch auf Elemente der MMP und TIMP Klasse wirken, vielversprechend in der 
Krebstherapie in Kombination mit Bestrahlung sein.
Diese Arbeit konnte aufzeigen, dass das Mikrotubulistabilisierende Agens Patupilone 
von grossem Interesse für die Krebsbehandlung ist. Es ist ein wirksamer Inhibitor von Tumor-
zellmigration und Tumorzellwachstum unter hypoxischen und normoxischen Bedingungen. 
Es konnte gezeigt werden, dass Patupilone einen radiosensitivierenden Effekt in vitro und 
noch stärker in vivo hat. Zusätzlich konnte gezeigt werden, dass Patupilone stahleninduzierte 
MMP-Aktivität und Invasion inhibiert. Da strahleninduzierte MMP-Aktivität möglicherweise 
eine Rolle in der Krebsfortschreitung spielt, könnte die Kombination von Patupilone mit 
Bestrahlung tatsächlich zu einem grossen Fortschritt in der Krebsbekämpfung führen.
v
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11 Introduction
1.1 Cancer and cancer treatment
1.1.1 Cancer: epidemiology and management 
Cancer is the common name for a group of more than 100 diseases generally characterised by 
uncontrolled cell proliferation and spread. Cells in almost every tissue of the body can give 
rise to cancer, and malignancies can be classified by site of origin: carcinomas – cancers of 
epithelial origin, sarcomas originate from mesenchymal tissue, leukemias – from hematopoietic 
cell lineage etc. When the growing cancer cell mass disrupts essential tissues and organs, 
the disease becomes lethal. According to the World Health Organization cancer causes 
20 % of deaths in the European region. With more than 3 million new cases and 1.7 million 
deaths each year, cancer remains the most important cause of death and morbidity in Europe 
after cardiovascular diseases. The most frequent cancers among men are lung, stomach, liver, 
colorectal, oesophagus and prostate; among women – breast, lung, stomach, colorectal and 
cervical (Fig 1.1, 1.2). A study on cancer epidemiology performed in 2008 showed that trends 
in incidence are actually generally favourable in the more prosperous countries from 
Northern and Western Europe, except for obesity related cancers and, for women, tobacco-
related cancers [1]. However, worldwide prognosis is not that favourable and according to 
the WHO estimation (done in 2004) deaths from cancer worldwide are projected to continue 
rising, with an estimated 12 million deaths in 2030. The unfavorable trends are mainly attrib-
uted to low-income countries, which have no adequate programs for cancer prevention and 
Figure 1.1. Dstrbuton of 
the cancer cases by gender 
n Europe n 2006 [1]
2treatment.
Cancer prevention includes healthy lifestyle and early diagnosis as some of the most 
common tumor types, including breast, colorectal and cervical cancer, can be cured if detected 
early. The three gold standard treatment strategies for cancer include surgery, radiotherapy 
and chemotherapy. Surgery is the oldest form of cancer treatment. About 60 % of all cancer 
patients will undergo surgery, which simply involves the removal of a malignant tumor. It 
works best on localized cancers that haven’t yet spread to other parts of the body, and is often 
followed by radiation therapy or chemotherapy to ensure that all malignant cells have been 
removed.
The other two treatment modalities are capitalizing on the fact that tumor cells are 
different from normal cells in terms of their proliferation rate and are therefore are much more 
sensitive to genotoxic stress. Radiation therapy is given to over 50 % of cancer patients. The 
modern, state of the art irradiation techniques allow to deliver very high radiation doses 
specifically to the tumor, while substantially sparing the surrounding healthy tissue. Chemo-
therapy is the general term for any treatment involving the use of chemical agents to prevent 
the growth of cancer cells. It allows to treat systemic oncological diseases, such as lympho-
mas, and the elimination of cancer cells that have already been involved in the metastatic 
process. More than half of all people diagnosed with cancer receive chemotherapy. Very often 
different treatment strategies are combined to achive the best treatment outcome.
1.1.2 Tumor biology
Over the previous decades, a complex body of knowledge was generated, which brought a 
substantial understanding of cancer biology. At the very end of the 20th century, D. Hanahan 
and R. Weinberg [2] formulated a set of rules that govern the malignant transformation. They 
highlighted six hallmark capabilities (Fig. 1.3) that a normal cell must acquire to become a 
malignant cell: 
(1) “Self-sufficiency in growth signals”: In contrast to normal cells, cancer cells do not 
Figure 1.2. Dstrbuton of 
cancer death by gender n 
Europe n 2006 [1]
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3depend on external mitogenic growth factors (GF) for proliferation. This can be achieved, for 
example, by overexpression of GF receptors (e.g. the epidermal GF receptor Erb) or by consti-
tutive activation of members of growth signaling pathways (e.g. mutations in ras gene) (2) 
“Insensitivity to growth-inhibitory signals”: Cells in a normal tissue are maintained quiescent 
either by antigrowth signals that force them to exit cell cycle or by acquisition of a differentiated 
state. Cancer cells can become desensitized to these signals by downregulation of responsible 
genes, such as pRb protein – negative regulator of cell cycle progression, or overexpression of 
proteins to avoid differentiation, for example c-Myc. (3) “Evasion of programmed cell death 
(apoptosis)”: Apoptosis can be triggered in a cell as a response to abnormalities (for example 
a signaling imbalance), and therefore it is important for cancer cells to learn to evade it. This 
can be achieved through the upregulation of anti-apoptotic proteins (Bcl-2) or downregula-
tion of the function of pro-apoptotic regulators (mutations in p53). (4) “Limitless replicative 
potential”: Normal cells have the capacity for 60-70 doublings due to telomere shortening. 
As many cells in the tumor are dying due to unfavorable mutations and harsh environmental 
conditions, the surviving cancer cells must acquire the ability to multiply infinitely to increase 
tumor mass. Cancer cells acquire limitless replicative potential by over-expressing the 
telomerase enzyme. (5) “Sustained angiogenesis”: To be able to progress to a larger size, tu-
mor must provide itself with a sufficient nutrient and oxygen supply. In order to do so, cancer 
cells must develop an angiogenic ability that seems to be acquired by changing the balance of 
pro- and anti-angiogenic factors – the so-called “angiogenic switch”. The tumor environment 
seems to play an important role in this process, as will be discussed in more details in chapter 
1.1.3. (6) “Tissue invasion and metastasis” is one of the latest features that are acquired by 
cancer cells. The requirements for successful cell invasion include: first, changes in physical 
interaction with the environment; second, acquisition of a sufficient level of motility; and, 
last, the ability to degrade the extracellular matrix (ECM). Cancer cells alter the regulation of 
Figure 1.3. Pathways of tu-
morgeness. The sx hallmark 
capabltes of cancer (self-
sufficiency in growth factors, 
nsenstvty to ant-growth 
signals, evading apoptosis, 
limitless replicative potential, 
sustaned angogeness and 
tssue nvason and metasta-
ss) are acqured n varable 
order across the spectrum of 
cancer types and subtypes. 
Adapted from [2].
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4cell-cell and cell-matrix adhesions by means such as deactivating the E-cadherin and chang-
ing the integrin isoform composition. Tumor cells also over-express extracellular proteases 
(matrix metalloproteinases) for extensive ECM degradation [2].
These hallmark capabilities should be acquired through genetic mutations. It is 
considered that “mutator mutations” must occur that lead to so-called genetic instability – an 
enhanced rate of changes in nucleotide sequence or of chromosomal rearrangements. The ge-
netic instability, in turn, provokes further mutations, which can potentially lead to pro-malignant 
changes and “mutator phenotype”. The “mutator mutations” are most likely to be in genes 
that are important for DNA damage repair and cell cycle checkpoints. They can be inherited 
or occur sporadically over a life span as a result of exposure to environmental factors and ag-
ing [3].
1.1.3 Tumor microenvironment
The tumor is a complex organ-like structure with cancer cells and stromal cells being in close 
interaction. Tumor associated stromal cells are recruited from surrounding normal tissue or 
from circulation. Classically recognized components of the tumor stroma include connec-
tive tissue, blood vessels, inflammatory cells and fibroblasts [4]. The tumor stroma provides 
growth factors and cytokines, thereby influencing the proliferation and invasion of tumor 
cells, angiogenesis and metastasis. Physical characteristics of the tumor microenvironment 
(TME) also play an important role in cancer progression. One of them is tumor hypoxia – a 
condition that results from an imbalance of oxygen delivery and oxygen consumption in the 
tumor and is characterized by the low oxygen content in the tumor. Hypoxia induces defined 
pattern of specific gene transcription, which leads to an adaptation ofthe tumor to low oxygen 
condition. The hypoxia-induced transcription factor-1α (HIF-1α) upregulates the expression 
of pro-angiogenic proteins, such as the vascular endothelial growth factor (VEGF). Moreover, 
the HIF-1α signalling pathway is important for tumor cell dissemination [5-6] and the sur-
vival of tumor cells at the metastatic site [7]. 
Secreted proteins are another essential component of the TME. One example is the 
aforementioned VEGF, which is secreted by tumor cells and induces the proliferation of 
endothelial cells during angiogenesis. Another example is secreted proteases, such as MMPs 
(matrix metalloproteinases), which participate in multiple tumor-related processes (including 
metastatic invasion and angiogenesis) by controlling bioavailability of the regulatory fac-
tors. Specific tumor types are associated with a unique tumor stroma. For example 50 % 
of an invasive breast tumor’s mass may consist of tumor-associated macrophages (TAMs); 
similarly, fibroblasts are the predominant component found in the stroma of colon cancer [8]. 
Multiple studies have shown that unique stromal elements (such as cancer-associated fibro-
blasts and TAMs (rev in [4]), as well as tumor hypoxic status [9] correlate with poor disease 
prognosis. The tumor-associated stromal cells can contribute to the treatment response by sup-
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they themselves should be less prone to develop drug resistance. Therefore targeting stromal 
cells (e.g. angiogenic vessels) or their products (for example, VEGF) is a good strategy for 
cancer therapy and for overcoming the problem of treatment resistance [10-11].
1.1.4 Cell migration and metastasis
Cancer cells possess a broad spectrum of migration and invasion mechanisms. These include 
both individual and collective cell migration strategies. Generally speaking, invasion requires 
migration, adhesion and proteolysis of extracellular matrix components. First, the moving 
cell becomes polarized and elongates. The cell protrudes its leading edge, which attaches to 
the ECM substrate. Subsequently, regions of the leading edge or the entire cell body contract, 
thereby generating traction force that leads to the gradual forward gliding of the cell body and 
its trailing edge. The migration of cells is a cyclical process that requires interplay between 
the microtubule and actin cytoskeletal systems. The microtubule growth occurs at the leading 
edge and microtubule shortening occurs at the cell body and rear. Microtubule growth and 
shortening may activate Rac1 and RhoA signalling respectively, to control actin dynamics. 
Rac1 activity at the leading edge promotes actin assembly at the leading edge. RhoA activity 
in the cell body drives actomyosin contractility and the formation of actin bundles and focal 
adhesions, increasing contractility in the direction of migration, possibly causing further 
microtubule breakage in the cell body. Thus, the dynamic interactions between microtubules 
and actin may provide a positive feedback loop to drive cell migration [12]. 
The turnover of adhesions is critical for affective migration. Integrins come into contact 
with ECM ligands and cluster in the cell membrane. Clustered integrins recruit adaptor and 
signalling proteins (like α-actinin, the focal adhesion kinase (FAK), vinculin, paxillin), forming 
the adhesion focal complexes. The adhesions provide the required traction for the cell to pull 
forward. At the same time, disassembly of the adhesion complexes at the rear of the cell is 
necessary to enable forward progress. As a result of ECM sensing, surface proteases become 
Figure 1.4. Metastatc process. Cancer cells can 
dssemnate from the prmary ste va lymphatc routes 
(red arrows) and by haematogenous routes (blue ar-
rows). Secondary haematogenous dssemnaton also 
occurs from overt metastases to other dstant stes 
(black arrows) [16].
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cleave ECM components (such as collagen, fibronectin and laminins) as well as pro-MMPs to 
create active soluble MMPs, such as MMP-2. MT1-MMP, MMP-1 and other collagenases cleave 
native collagens, along with other ECM macromolecules, into smaller fragments. These in 
turn, are accessible to subsequent degradation by gelatinases (MMP-2 and MMP-9) or serine 
proteases [13].
The process of tumor cell dissemination and metastasis is understood as the migration of 
individual cells, which detach from the primary tumor, enter lymphatic vessels or the blood-
stream and seed in distant organs (Fig. 1.4). Mechanical factors influence the initial fate of 
disseminating cancer cells. Blood flow determines to which organ the cancer cell will travel 
first. As the relatively large size of tumor cells does not allow them to pass through capillaries, 
the disseminating cells get arrested in the first capillary bed they encounter. However, the 
ability of the cancer cell to proliferate at the metastatic site is determined by the molecular 
interactions with the organ environment. The “seed (cancer cell) and soil (factors in the organ 
environment)” theory claims that as a result of these interactions, tumors have an organ-
specific pattern of metastasis. For example, breast cancer frequently metastasizes to bone, 
brain and lungs; prostate cancer preferentially spreads to bone [14]. Due to the complexity of 
the process and multiple challenges for the tumor cell (such as survival in a blood stream and 
growth in a foreign environment) metastatic process is highly inefficient. Nevertheless, it is 
the main cause of cancer-related morbidity, as cell invasion has proved to be difficult to block 
safely and effectively with pharmacological compounds [13, 15].
1.2 Radiation therapy
1.2.1 Mechanisms of cytotoxicity
Conventional radiation therapy is usually applied with a beam composed of x-rays (photons). 
When radiation initially interacts with biologic matter, direct or indirect ionizations take place. 
The mechanism of ionization by x-rays is deemed “indirect” when the effects are caused by 
secondary particles. Ionizing radiation gives rise to fast (high energy), charged secondary 
particles (electrons), which can then directly or indirectly cause ionizations in the critical 
target molecules (e.g. DNA). The predominant interaction usually takes place with the most 
abundant cellular medium, water. The series of reactions that will follow are known as radi-
olysis of water and result in production of free radicals. In the presence of oxygen, the free 
radicals will produce RO2, organic peroxides (reactive oxygen species – ROS), which are 
highly reactive. In a cell, IR may damage almost any components, including proteins and lip-
ids in the cell membrane [17-18]. DNA damage, however, is the most relevant for cell killing 
[19].
Damage to DNA can be classified into a number of general classes that include dimers, 
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breaks (DSB). To be able to repair the DNA damage a cell has mechanisms for DNA damage 
sensing that activate signal transduction pathways, which in turn orchestrate multiple cellular 
functions for successful damage repair. DSBs are the most complex lesions and therefore they 
are the greatest threat for cell survival as the lack of an intact template DNA strand makes 
repair of the DSB difficult and error-prone. The two well-described DSB repair strategies 
are termed homologous recombination (HR) and non-homologous end-joining (NHEJ). The 
fundamental difference between the two is the dependence on DNA homology in the former. 
Therefore HR plays a more prominent role during late S and G2 phases of the cell cycle, when 
the sister chromatid DNA strands are available. NHEJ uses little to no sequence homology for 
repair and therefore it is more important during G1 and early S phase [20].
Radiation leads to cell death by way of different mechanisms (Fig. 1.5). Even low 
doses of irradiation, as a stress factor, can induce fast apoptosis in interphase in some 
cells. Apoptosis is an active process characterized by programmed cell death in which a 
defined cascade of events takes place. Various factors may modulate the apoptotic response 
to DNA damage, including the p53 status of the cell and levels and activity of the pro- and 
anti-apoptotic proteins. The ability to evade apoptosis is one of the features exhibited by 
cancer, however, there seems to be no direct correlation of apoptosis and radiosensitivity. A 
basic principle in the radiobiology of tumors is that an essential difference exists between cell 
death and the loss of reproductive integrity of tumor cells, so-called clonogenicity, and for the 
outcome of curative RT the latter matters most [21]. 
If cells do not undergo apoptotic death in interphase, they may become arrested in G1 
and/or G2 phases of the cell cycle and then, as soon as the repair processes are accomplished, 
continue to proliferate. However, if the DNA damage was not sufficiently repaired during 
the arrest, the fate of the cell develops according to different scenarios that lead to either cell 
death or to loss of clonogenicity. The possible mechanisms include: (i) mitotic catastrophe – a 
result of aberrant mitosis, characterized by formation of nuclear envelopes around individual 
clusters of missaggregated chromosomes; (ii) senescence – a state when cells loose their abil-
Figure 1.5. Cell fate after IR-nduced DNA 
damage.
1.2 Radiation therapy
8ity to proliferate but keep on metabolizing or (iii) autophagy – another type of programmed 
cell death which is characterised by the appearance of autophagic vacuoles in the cytoplasm. 
The cells death via mitotic catastrophe can have phenotypic sings of apoptosis or necrosis (a 
passive cell death process, characterised by disintegration of nuclear and cellular envelope) 
[21-24]. 
Radiotherapy (RT) is one of the most prevalent cancer treatments. The goal of radio-
therapy is to increase the total radiation dose to tumor tissue, while simultaneously limiting 
the toxicity in surrounding normal tissues to a tolerable degree. This goal can best be achieved 
by high accuracy conformal techniques and a sensitive fractionation schedule, where the total 
dose is applied in multiple (up to 35) small daily fractions. Fractionation helps to reduce dose 
limiting toxicities, by employing the major differences between cancer and normal cells: most 
cancer cells are DNA damage repair (DDR)-impaired and proliferate more rapidly than most 
normal cells. It has been speculated that DDR inhibition might enhance the effectiveness of 
radiotherapy and DNA-damaging chemotherapies. Indeed, various DDR-inhibitory drugs are 
in preclinical and clinical development to test this premise [25].
1.2.2 Unfavourable effects of radiation therapy: focus on metastasis
In spite of the persistent effort to enhance the precision of modern radiation therapy, normal 
tissue toxicity still has to be taken into consideration. Nowadays, acute side effects of RT are 
generally clinically manageable but late side effects (such as secondary tumors at the irradiated 
site) remain an important issue especially for treatment of childhood cancers [26]. Another 
aspect, which is regularly reported in literature, is the potential pro-metastatic effect of IR. 
However, there are no comprehensive studies of this problem and it is difficult to draw a firm 
conclusion from the existing reports because of the heterogeneity of patient cohorts (age, race 
and gender, tumor sites, staging), treatments applied (dose and fractionation of RT, target 
of RT, combination with surgery and chemotherapy), response to treatment (local failure or 
local control), diagnosis of metastasis (including autopsy or not) and methods of statistical 
analysis. The overall impression however remains that under certain circumstances RT favors 
metastasis. The experimental evidence occur that ionizing radiation can upregulate metastasis-
related processes [27]. 
IR was shown to induce matrix metalloproteinases (MMPs, see Chapter 1.4) and cell 
invasion, not only in in vitro assays [28-31], but also in in vivo mouse models. The use of 
radiation for treating primary murine lung (LLC-LM) tumors resulted in the growth of 
previously dormant lung metastases [32]. Fractionated irradiation of prostate cancer xeno-
grafts in mice led to local tumor control but increased disseminated metastases, whereas 
non-irradiated local xenografts failed to disseminate. In this study a correlation was found 
between the appearance of irradiation-induced metastases and enhanced activity of MMP-9 in 
the urine of irradiated mice [33]. Though the activation of MMPs by IR is a well-established 
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invasion in vitro [34-35] and in pre-clinical studies, for example IR decreased the occurrence 
of lung metastasis in mice bearing mammary carcinoma. The role of radiation treatment in 
metastatic processes is a matter of great debate and seems to be strongly dependent on the tu-
mor type and the experimental system that was used in the study. However, the pro-metastatic 
action of RT may explain why the better local control achieved by this treatment modality 
fails to be translated into longer survival, free of distant metastasis, and that the better radio-
therapeutic strategies must aim at a better metastasis control [27].
1.3 Microtubules as a target for cancer treatment
1.3.1 Tubulins 
α- and β-tubulins are the two families of the tubulin superfamily that were discovered first 
and have been since studied in most detail. They form heterodimers that build microtubules 
(MT) (Fig. 1.6). Seven known isotypes of β-tubulin are mainly tissue specific: βI- and βIVb-
tubulins are constitutively expressed in main cell types; βII is a major isotype in neurons; βIII 
is also found in neurons and increased in several tumor types being associated with aggres-
sive and invasive disease; βIVa is brain specific; βV is specific for uterus and endometrium 
and was found in adenocarcinomas; and βVI-tubulin is located in hepatopoesis-specific cells. 
The tubulin isotypes within one tubulin family share a high degree of homology and differ in 
the C-terminal region of 20-27 amino acids. Further members of the tubulin family include 
the γ-tubulin (a protein, which plays a role in microtubule nucleation) and the four recently 
Figure 1.6. Structure of microtubules. α- and 
β-tubulin heterodimers are associated end-to-
end into a protofilament. Protofilaments side-
by-sde packng forms the wall of the mcrotu-
bule [43].
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discovered tubulins – delta (Δ)-, epsilon (ε)-, zeta (ζ)- and eta (η)-tubulin. The functions 
and localization of the four “new” tubulins are associated with the eukaryotic centrosomes 
and other MT organizing centers (MTOCs) [36]. α- and β-tubulins are subject for a number 
of translational modifications including acetylation, tyrosination, phosphorylation, polyglu-
tamilation and polyglycylation. Most α-tubulins are known to be acetylated in stabilized 
MTs after assembly. Stable microtubules also appear to be more detyrosinated. A substantial 
tubulin and microtubule diversity is created due to tubulin post-translational modifications 
together with multiple tubulin isotypes, but the biological meaning of this diversity is not yet 
well understood  [37].
There are known β-tubulin mutations that lead to insensitivity of cells to MT-interfering 
cytotoxic drugs. These mutations can be obtained as a result of directed cell selection. For 
example, the Gln to Glu mutation at residue 292 of βI-tubulin in A549 human lung tumor cells 
led to a phenotype 100-fold more resistant  to epothilone B [38], and the Asp to Glu mutation 
at residue 26 resulted in a phenotype 20-fold more resistant to paclitaxel [39]. However, spon-
taneous mutations of this kind are typically rare events and therefore not clinically relevant 
[40]. What really causes insensitivity of tumor cells to therapy with MT-interfering drugs is 
a change in the isotype composition of tubulins, which forms microtubules in cancer cells 
[41]. Overexpression of βIII-tubulin is associated with resistance of ovarian, breast, NCLC 
and other cancer types to both, the MT-stabilizing compounds from the taxan group and the 
MT-destabilizers vinca alkaloids. Overexpression of “harmless” tubulin types, like βI and βII, 
can also lead to drug-resistance (reviewed in [42]).
1.3.2 Microtubules and their cellular functions
Microtubules are polymeric molecules built of α- and β-tubulin heterodimers. The heterodimers 
are associated end-to-end into a protofilament. Their side-by-side packing forms the wall of 
the microtubule (usually 13 filaments, form a cylindrical microtubule with an outer diameter 
of 25 nm) (Fig. 1.6). The microtubules display structural polarity in which the addition of 
subunits occurs preferentially at one end designated the (+) end. The other end is called the (-) 
end and is usually oriented towards MTOC [44-45]. Microtubules are highly dynamic and can 
switch stochastically between phases of growth and shortening. This non-equilibrium behaviour, 
known as dynamic instability, is based on the binding and hydrolysis of GTP by tubulin sub-
units. Each tubulin monomer binds one molecule of GTP. The binding of GTP to α-tubulin at 
the N-site is non-exchangeable, whereas the binding to β-tubulin at the E-site is exchangeable. 
Only tubulin dimers with GTP in their E-site can polymerize, but after polymerization 
this nucleotide is hydrolyzed and becomes non-exchangeable. The most favoured hypothesis 
to explain dynamic instability is the GTP cap model. In this model, the body of the microtu-
bule is made of GDP-tubulin subunits and is therefore unstable. The microtubule structure is 
only stabilized by a layer of tubulin subunits at the ends that still retain their GTP. When this 
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cap is stochastically lost, the microtubule rapidly depolymerizes. Microtubule assembly and 
stability, which are self-regulated by the nucleotide state of tubulin, are further modified in the 
cell by interaction with cellular protein factors (MT-binding proteins), which can stabilize or 
destabilize microtubules at different points in the cell or at different stages in the cell cycle. 
Microtubule growth is promoted in a dividing or moving cells and is better controlled in a 
stable, polarized cells [46].
Microtubules are an essential part of the cytoskeleton. They are involved in almost all 
major vital processes in eukaryotic cells including cell division, motility, intracellular 
organelle trafficking and interaction with the environment. Mostly importantly, microtubules 
are responsible for the organization of the mitotic spindle during cell division. During mitosis 
MTs are 4-100-fold more dynamic than in interphase [47]. Highly dynamic microtubules are 
required for the correct attachment of chromosomes, for the transportation of the chromo-
somes to the metaphase plane, and for the synchronous separation of chromosomes to two 
daughter cells. Furthermore, microtubules are necessary for cell polarization and the regu-
lation of cellular adhesion during cell migration. The microtubule growth and disassembly 
locally activate small Rho GTP-ases which regulate actin assembly and contractivity [12]. It 
was demonstrated that vasicular transport within the cell is facilitated by MTs, and may even 
be dependent on them. Vesicles were shown to be localized adjacent to microtubular struc-
tures and MT-interfering agents can inhibit protein secretion [48] and exocytic responses [49]. 
The crucial role of microtubules in all these cellular processes, and mainly in cell division, 
makes them a very attractive target for anti-tumor therapy. 
1.3.3 Microtubule stabilizing agents (MTSAs)
Compounds targeting microtubules are one of the most important class of anti-cancer agents. 
Microtubule-interfering agents are divided in two groups according to their mode of action. 
Microtubule destabilizers are compounds that prevent the assembly of tubulin heterodimers. 
Treatment with these compounds leads to the disruption of the MT system in the cell and 
makes all processes involving MTs (including cell division) impossible. Vincristine, the first 
MT-interfering agent approved for clinical use, belongs to this group [50]. The two main 
groups of microtubule stabilizers are taxanes and epothilones (Fig. 1.7) [51]. Over the last 
half century since MT-stabilizers were discovered, a substantial number of these compounds 
made there way towards clinical use. Multiple studies on their molecular mechanism of ac-
tion brought rationales for combination of MT-stabilizers with other treatment modalities in 
cancer treatment.    
Taxanes. Paclitaxel (taxol) was discovered in 1971 as part of an anti-cancer drug screen 
[52]. It was isolated from an extract of the bark from a rare yew, Taxus brevifolia. In a search 
for a more abundant supply, docetaxel (taxotere) was developed, which is synthesized from 
an inactive taxane precursor found in more abundant yew species [51]. Since the 1990s, 
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paclitaxel and docetaxel were approved by FDA [53-54] for a broad range of indications, 
including advanced breast cancer [55-56], high-grade ovarian cancer, non-small cell lung 
cancer [57] and also for a number of other tumors [58].
Epothilones. The epothilones are non-taxoid MT-stabilizers of bacterial origin, which 
share the binding site on beta-tubulin with taxanes [53, 59-61]. Epothilones are the most clini-
cally promising MT-stabilizing compounds, as they offer a number of advantages: (i) they 
are very potent MT-stabilizers with cytotoxicity in the low nanomolar concentration range; 
(ii) they come from an abundant supply and can be obtained by bacterial fermentation; (iii) 
they are a worse substrate for the P-glycoprotein than taxanes and thus more effective than 
paclitaxel in cells which acquired multidrug resistance; (iv) due to their relatively simple mo-
lecular architecture, epothilone derivatives with more favourable pharmacological profile are 
available [62]. Different members of the epothilone family are currently in various stages of 
clinical development as antitumor compounds. Ixabepilone is the first FDA approved drug in 
this class and indicated for the treatment of patients with metastatic breast cancer. Patupilone 
is tested in a wide spectrum of phase II studies, including those for recurrent glioblastoma, 
prostate, cervical, renal cell, gastric and lung tumors [63].
1.3.4 Biological effects of microtubule stabilizing agents 
Taxanes and epothilones bind to beta-tubulin in a close proximity to residue Thr274 [64]. 
Compounds from both groups can induce polymerization of the purified tubulin heterodimers, 
even under extremely unfavourable conditions and stabilize microtubules under depolymerising 
conditions [61, 65]. Exposure to epothilones and taxanes prevents shortening of MT resulting 
in the accumulation of polymerized MT molecules, which then form bundles in the cytoplasm 
[61, 66-68]. At lower doses of MTSAs, MT bundles formation cannot be observed but a signifi-
Figure 1.7. Chemcal struc-
ture of MT-stablzng agents 
[51].
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cant deceleration of microtubule dynamics does occur [60, 69].
MTSAs activate intracellular signalling pathways and can influence transcription. On 
the transcriptional level, MTSAs were shown to induce genes responsible for stress response 
and cell cycle checkpoints [70-71]. On the level of intracellular cell signalling, paclitaxel was 
shown to induce the PI3K/Akt pathway [72]. Several reports indicate the induction of the 
NF-kB pathway after treatment with MTSAs [73-75]. There is no clear understanding as to 
whether these signalling and transcriptional events are a consequence of MT-function inhibition 
or MT- independent events. Quite likely, it is the former, however, there is a dearth of systemical 
studies of this problem.
The treatment of cells with MTSAs inhibits cell proliferation. Classical mechanism, 
which was first discovered for taxanes, is induction of M-phase arrest as a result of MT-bundling 
and destruction of mitotic spindle [61, 69, 71, 76]. This old dogma that cytotoxic effects of 
MTSAs are related to the induction of M phase arrest is hardly questioned nowadays. After 
incubation with low concentrations of MTSAs, aberrant mitosis takes place. This is a con-
sequence of multipolar spindle formation, which results in aneuploid cells, arresting in G1 
afterwards [71, 77-78]. It was also shown in human colon carcinoma cells that patupilone is 
cytotoxic at concentrations that do not induce the M-phase arrest but lead to S phase 
accumulation [79]. Whatever happens to a cell, be it cell cycle arrest or aberrant mitosis, it 
will eventually lead to cell death either by classical p53-dependent apoptosis [61, 69, 71] or 
by alternative mechanisms, like mitotic death [80].
MTSAs can inhibit processes that are necessary for cell invasion. Paclitaxel was shown 
to inhibit migration of multiple cell types, including endothelial cells [81-83], smooth muscle 
cells [84] and tumor cells of different origin [85-87]. For example, it reduced the invasive 
activity of melanoma cells by impairing the secretion of MMP-2/MMP-9 [48]. Patupilone 
was also shown to inhibit endothelial cell migration [88]. These findings suggest that MTSAs 
must be effective inhibitors of metastatic processes and, indeed, there are pre-clinical reports 
in the literature, which support this supposition. When tested on mice, paclitaxel inhibited 
melanoma metastasis to the lung in vivo in a spontaneous melanoma metastases model [89] 
and in a 4T1 breast cancer model [90]. Patupilone reduced brain metastases in a human 
prostate xenograft [91] and in a human NSCLC xenograft model in nude mice [92]. 
Sagopilone (another member of the epothilone family) inhibited breast cancer bone me-
tastasis in breast metastatic mouse model [93]. 
Due to the strong cytotoxic potency of MTSAs against proliferating cells, they are 
successfully used as anti-neoplastic drugs nowadays (rev [60]) and their potential anti-meta-
static action makes them even more attractive chemotherapeutics for anti-cancer therapy.
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1.4 Matrix metalloproteinases and tissue inhibitors of matrix                                
      metalloproteinases
1.4.1 Matrix metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases. They are mosaic proteins, 
each constituted by a modular combination of inserts and domains (Fig. 1.8). MMP proteins 
may include (from N- to C-terminus) a signal peptide for secretion, a ~80-residue zymogenic 
pro-peptide, a ~165-residue zinc- and calcium-dependent catalytic metalloprotein domain 
and a hemopexin-like domain for collagen binding, pro-MMP activation and dimerization. 
Gelatinases A (MMP-2) and B (MMP-9) contain additionally a fibronectin-related domain 
for interaction with collagens and gelatins. Membrane type MMPs (MT-MMPs) also have 
a trans-membrane domain, a membrane linker and a cytoplasmic tail. In humans, 23 MMPs 
Figure 1.8. Schematc representaton of the structure of the 24 human matrx metalloprotenases 
(MMPs). Y, D, and G represent tyrosine, aspartic acid and glycine amino acids that are present in 
the catalytic domain of all collagenases. GPI – glycosylphosphatidylinositol membrane anchor, 
TM – type I or type II transmembrane segments, CA – cysteine array, Ig – immunoglobulin domains 
[97].
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were described; these are numbered 1 to 3, 7 to 17, 19 to 21 and 23 to 28 for historical reasons. 
They can be divided into the following categories based on their preferable substrates: (i) true 
collagenases (MMP-1, -8, -13), which cut triple-helical collagen at a single site across the 
three chains; (ii) gelatinases (MMP-2, -9), which target denatured collagens and gelatins; and 
(iii) stromelysins (MMP-3, -10, -11), which have broad specificity and may degrade proteo-
glycans. MMPs overlap substantially in substrate specificity and in cellular localization and 
this complicates investigation of their biological functions [94-95].
Regulation of MMPs. MMPs are regulated via modulation of their gene expression, 
compartmentalization and inhibition by protein inhibitors. The promoter regions of MMPs 
contain multiple transcription factor-binding sites (Fig. 1.9), for example the activator pro-
teins (AP)-1 and -2 sites, the nuclear factor kB (NF-kB) site, the retinoblastoma control ele-
ment (RCE), the TATA-box (TATA) [96-97] etc. Therefore, the transcription of MMPs can 
be variously regulated by different intra- and extracellular signalling. For example, increased 
Figure 1.9. Regulatory elements 
n the promoter regons of hu-
man MMP genes. The promoters 
are shown in the direction 5′-3′, 
wth the transcrpton start stes 
indicated with a bent arrow, and 
the transcrpton-factor-bndng 
stes placed wthn boxes. The 
relatve postons of the dfferent 
elements are not drawn to scale. 
AGRE – the AG-rich element; 
AP – the activator proteins-1 and 
-2 site; CBFA1 – the core-bind-
ing factor 1 site; C/EBP – the 
CCAAT/enhancer-binding protein 
site; CIZ – the CAS-interacting 
zinc-finger protein site; CREB 
– the cyclic AMP response-ele-
ment binding protein site; EGR1 
– the early growth response-1 
site; ISE – the immortalization-sensitive elements-1, and -2; KRE – the keratinocyte differentiation-factor respon-
sive element; NF-κB – the nuclear factor of κB site; PEA3 – the polyomavirus enhancer-A binding-protein-3 site; 
RARE – the retinoic-acid response element; RCE – the retinoblastoma control element; SPRE – the stromelysin-1 
platelet-derived growth factor-β responsive element; STAT – the signal transducer and activator of transcription 
site; TATA – the TATA-box; TBS – the TEL (translocation-ETS-leukaemia) binding site; TCF – the T-cell factor site; 
TIE – the transforming growth factor-β inhibitory element site; ZBP-89 -– the binding site for 89-kDa zinc-binding 
proten [97].
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activation of the WNT pathway increases the expression of MMP-2, -7, -9 and MMP-14 
(MT1-MMP) as their promoters contain putative TCF-binding sites [98-99]. PI3K/Akt and 
p38/Akt pathways were shown to upregulate MMP-2 production in glioma cells after IR [100]. 
IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- 
and ERK1/2-dependent NF-kB and AP-1 activation [101].  The NF-kB pathway activation 
was also shown to induce MMP-9 [102] and MMP-3 [103].
MMPs are expressed as inactive zymogens. Their proteolytic site is shielded by a 
pro-domain which must be cleaved for zymogen activation. About one-third of MMPs, 
including all membrane-bound MMPs, are activated in the intracellular compartment. These 
MMPs have the convertase cleavage sites (RXKR or RRKR), which are target for pro-protein 
convertases or furins (serine proteases present in the Golgi network) [104]. For many other 
MMPs, the mechanism of activation is more presumed than proved. In ex vivo systems it was 
shown that MMPs can be activated by other MMPs [105] and plasmin [106]. However, there 
is no clear proof that this is also the case in vivo [107]. The only well described mechanism is 
the activation of proMMP-2 by MMP-14 (MT-MMP-1) in the presence of the tissue inhibitor 
of MMP-2 (TIMP-2) [108], which will be discussed in more detail below (Chapter 1.4.4).
The third level of MMP regulation is the inhibition of their enzymatic activity. There 
are several groups of natural MMP inhibitors. α2-macroglobulins (approximately 700 kDa 
glycoproteins) non-specifically inhibit endopeptidase activity in the plasma. They trap 
MMPs and the complexes of macroglobulins, and the complexes are cleared from plasma by 
endocytosis [96, 108-109]. Tissue inhibitors of MMPs (TIMPs) are a family of very potent in-
hibitors, which will be described in detail below (Chapter 1.4.3). Recently another inhibitor of 
MMPs was described – RECK (reversion-inducing-cysteine-rich protein with Kazal motifs) 
[110]. This transmembrane glycoprotein regulates at least three members of the MMP family: 
MMP-2, MMP-9 and MMP-14. This inhibitor seems to be of a particular interest as it is pres-
ent on the membranes of normal cells and lost during malignant transformation [111].
The last potential mechanism of MMP regulation, which has emerged only recently, 
is sub-cellular compartmentalization. It was shown that many secreted MMPs are not only 
released to the extracellular space but also remain associated with the cell membrane via 
integrins or other cellular receptors [107]. This allows to maintain a high density of proteases 
in the pericellular space. Endocytosis was also shown as a mechanism for MT1-MMP 
regulation [112]. Additionally, MMPs are secreted at least partially in vesicles [113-114], 
which allows for an additional potential mechanism of MMP regulation based on the MT and 
actin cytoskeleton.
1.4.2 Physiological role of MMPs
MMPs were discovered as enzymes that degrade structural components of the extracellular 
matrix (ECM) for cell invasion. However during the ECM degradation specific fragments 
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with independent biological activities can be produced. For example, the cleavage of laminin-5 
or collagen IV molecules results in the exposure of cryptic sites, which promote migration 
via integrin signaling. MMPs can also modify the activity of signaling molecules, as cleav-
age of ECM proteins can release ECM-bound growth factors, including insulin growth factor 
(IGF) and fibroblast growth factor (FGR) [115]. In recent years, a number of non-matrix sub-
strates of MMPs were identified. Precursors of molecules that alter cell growth are activated 
by MMP-mediated cleavage, such as IL1-β and insulin-like growth factor binding protein 
which is cleaved into active insulin growth factor ligand. MMP-7 was shown to participate 
in regulation of apoptosis by cleaving membrane-bound Fas ligand [116]. A role of MMP 
in intercellular communication has also been demonstrated. For example, MMP-9 is required 
for VEGF release for osteoblast recruitment during bone development [117].
By implication of genetic knock-outs, the functions of MMPs were linked to many vital 
biological processes, (e.g. embryonic development, organ morphogenesis, ovulation and 
endometrial cycling, hair follicle cycling, bone remodeling, wound healing, angiogenesis and 
apoptosis). If the enzymatic activity of MMPs is not subjected to a fine-tuned control, dys-
regulation can give rise to pathogenic activity. This occurs during inflammation, arthritis, 
fibrosis and cancer-associated processes [115, 118].
1.4.3 Tissue inhibitors of MMPs (TIMPs) 
The tissue inhibitor of MMPs (TIMP) family consists of four members, TIMP-1 to -4, which 
are substantially conserved throughout the evolution [119]. Members of the TIMP family 
share sequence homology [120] and about 40 % structural identity at the protein level. TIMPs 
have two structurally similar domains: an N-terminal domain with six conserved cysteine 
residues possessing MMP-inhibitory activity, and a C-terminal domain, which also contains 
six conserved cysteine residues [121]. All members of the family are secreted proteins. TIMP-3 
is noted for its ability to bind to the ECM [122].
Regulation of TIMPs. Whereas TIMP-2 is constitutive and widely expressed through-
out the body, TIMP-1, -3, -4 expression is inducible and often exhibits tissue specificity. 
TIMP-1 is enriched in reproductive organ systems, TIMP-3 in heart, kidney, and thymus, and 
TIMP-4 in brain, heart, ovary and skeletal muscle [123]. The regulation of TIMPs is not well 
studied. The upregulation occurs primarily at the transcriptional level involving transcription 
factors like AP-1 (TIMP-1, -2, -4), SP-1 (all TIMPs) and NF-kB (TIMP-2 and -4) transcription 
factors. The presence of an SP1 site in all TIMP promoters reflects the involvement of TIMPs 
in developmental processes. Tissue-specific promoter binding sites can be also found; for 
example, the promoter of TIMP-4 contains a myogenin-binding site, likely important for its 
skeletal muscle-specific expression [124]. 
Since the common promoter elements can be found both in MMPs and TIMPs (e.g. AP-
1, NF-kB) these proteins can be synchronously induced by extracellular stimuli, like growth 
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factors, cytokines (IL-1β) or phorbol ester (activator of PKC) [125-126]. However, an in-
creasing amount of evidence suggests the existence of signalling pathways that can lead to TIMP-
1 upregulation without MMP induction. For instance, erythropoietin regulates TIMP-1 and 
MMP-9 expression in an inversely coordinated manner [127] and the transforming growth 
factor-β1 (TGF-β1) upregulates TIMP-1 and downregulates MMP-1 by differentially utiliz-
ing the AP1 and Smad pathways [128].
1.4.4 Physiological role of TIMPs
The first known biological function of TIMPs, which led to their discovery, was the inhibition 
of MMPs. In the ECM, TIMPs form non-covalent 1:1 stoichiometric complexes with MMPs. 
Almost all MMPs can be inhibited by all 4 TIMPs, although differences in binding affinity 
have been reported. For example, it is known that TIMP-1 is a weak inhibitor for MT-MMPs 
[129]. The mechanism of inhibition is believed to be the following: TIMP molecules have a 
wedge-like shape, which fits into the active site cleft of an MMP, as would a substrate 
molecule. The conserved cysteine in the N-terminal domain, at least in TIMP-1, will sub-
sequently chelate the active zinc site thereby inactivating the MMP protein [120, 130].
Except MMP inhibition, TIMPs are also required for MMP activation. The process of 
proMMP-2 activation is well described. MTl-MMP (MMP-14) activates proMMP-2 by cleaving 
its pro-domain and TIMP-2 serves as an adaptor protein between the two MMPs. TIMP-2 
mediates proMMP-2 activation in a dose-dependent manner. A certain ratio of TIMP-2 and 
proMMP-2 must be maintained for optimum activation [131]. The proMMP-TIMP complex 
is formed between the C-terminal domain of the inhibitor and the C-terminal hemopexin do-
main of proMMP, thus both molecules maintain their proteolytic and inhibitory properties, re-
spectively. These non-inhibitory complexes between pro-gelatinases and TIMPs are restricted 
to proMMP-2 and TIMP-2, -3, or -4 on the one hand and to MMP-9 and TIMP-1 on the other. 
The significance of the latter complex is not clear, it could possibly play a role in proMMP-9 
activation, by analogy with the TIMP-2/MMP-2 case [108, 120, 132-134].
It is difficult to distinguish between biological functions of TIMPs that are fulfilled 
through MMP-related mechanisms (e.g. regulation of angiogenesis, cell growth and apoptosis) 
and their unique MMP-independent functions. In an attempt to differentiate between these 
functions, studies were performed involving small molecule MMP-inhibitors and TIMP 
mutants without MMP-binding activity. These studies could demonstrate that, independently 
of the MMP-inhibiting activity, TIMP-1 and TIMP-2 can promote growth of a wide range of 
cells, including cells of the erythroid lineage, smooth-muscle cells, keratinocytes, fibroblast 
and epithelial cells. The mitogenic signals of TIMPs are probably transduced through 
tyrosine-kinase receptor pathways; however, no receptors for TIMPs have been found thus 
far [122, 135-136]. Other MMP-independent functions are the anti-apoptotic effect of TIMP-1, 
demonstrated in Burkitt’s lymphoma cell lines [137] and the anti-angiogenic effect of TIMP-2 
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[138]. Taken together, TIMPs have a broad range of biological functions. The first set of 
functions is related to MMP activity-regulated processes, but the second considerable part is 
unrelated to MMPs and extended to direct cellular effects. 
1.4.5 Role of MMPs and TIMPs in cancer progression
The expression of TIMPs, MMPs and MMPs activity are increased in almost every type of 
human cancer. The expression rate positively correlates with an advanced tumor stage, 
increased metastasis and shortened survival [139-142]. Unlike classical oncogenes, MMPs 
and TIMPs are not upregulated by gene amplification or activating mutations. Their increased 
expression in tumors is most likely due to transcriptional changes, which can be a result of 
activated oncogenes (e.g. Ras) [143] or loss of tumor suppressors (for example p53) [144] 
which are involved in the regulation of MMP expression. In human tumors, cancer cells are 
not the only source of MMPs that can be also synthesized by stromal cells. MMPs and TIMPs, 
as their inhibitors, are involved in several steps of cancer development and paradoxically 
implicated in both cancer promotion and inhibition. The pathways leading to opposing 
effects on cancer progression are sometimes initiated by cleavage of the same MMP substrate 
[139]. 
The diversity of MMP functions in cancer is illustrated in Figure 1.10. An example of a 
controversial effect of MMPs on tumor growth is the regulation of the transforming growth 
Figure 1.10. Promotng and nhbtng functons of MMPs n cancer progresson [139].
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factor-β (TGF-β) pathway. TGF-β normally exerts tumor-suppressive effects by enforcing 
cytostasis and differentiation. This factor can be proteolytically activated by MMPs. 
However, since the tumor cells often acquire non-responsiveness to TGF-β, the proteolytic acti-
vation of TGF-β by MMPs may have tumor-promoting effects by selectively driving stroma-
mediated invasion. MMPs promote the survival of cancer cells also by liberating IGF and 
cleaving FAS death receptor ligand (FASL). MMPs can also indirectly promote apoptosis by 
changing the ECM composition, which influences integrin signalling (Fig 1.10, b). MMPs 
promote angiogenesis not only by promoting endothelial cell invasion but also by increasing the 
bioavailability of the pro-angiogenic growth factors, like VEGF. MMPs also inhibit angio-
genesis through the generation of the anti-angiogenic factors angiostatin and endostatin (Fig. 
1.10, c). MMPs positively regulate invasion by degrading structural ECM components and by 
cleavage of adhesion molecules and E-cadherin. MMPs have the potential to inhibit metas-
tasis, as they cleave SDF-1, a chemokine of the CXC family that promotes breast cancer 
metastasis (Fig. 1.10, d). MMPs promote the epithelial-to-mesenchymal transition (EMT) 
– a process, which is associated with cell dedifferentiation during malignant transformation 
– by cleaving the cell-adhesion molecule E-cadherin and by liberating TGF-β. MMP-9 
can also promote differentiation by mechanism that is thus far unknown [139] (Fig. 1.10, e). 
MMPs are involved in immune reactions against cancer cells. For example, MMP cleavage 
of the IL-2 receptor-α (IL-2Rα) on T lymphocytes results in inhibition of the T-lymphocyte 
proliferation (reviewed in [132, 139]). 
Over the past few years, it has become clear that MMPs do more than just promote invasion 
and metastasis by degradation of the ECM proteins. The opposing functions of MMPs make 
them simultaneously act as tumor promoting and inhibiting factors, but most of the literature 
supports the opinion that the sum of MMP actions promotes cancer progression. MMP 
inhibitors are potential contributors to cancer treatment; however, such inhibitors for neoplastic 
treatment must be used with care, as the MMP functions that inhibit cancer progression must 
be taken into consideration.
1.5 Combined treatment modality of MTSAs and IR:                        
      radioenhancing mechanisms
The clinical objective of combining drugs with radiation is to improve survival without 
compromising life quality of patients. Much of clinical and experimental work on the 
combined treatment modalities to date has been empirically rather than rationally driven. 
With the recent emergence of knowledge in molecular oncology, new combination therapy 
strategies are being proposed that better capitalize on mechanisms of drug-radiation interac-
tions. In their article Bentzen et al [145] proposed five mechanisms for a rational design and 
analysis of drug-radiation therapies: (i) spatial cooperation – a strategy employing combined 
treatment to target locoregional and systemic disease; (ii) cytotoxic enhancement – increased 
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cell killing by modulating repair of cellular DNA damage; (iii) biological cooperation – tar-
geting distinct cell populations or employing different mechanisms for cell killing; (iv) 
temporal modulation – enhancing tumor response to fractionated radiotherapy and (v) normal 
tissue protection (Figure 1.11). 
The combination of MTSAs with IR involves direct drug-radiation interactions at the 
cellular level – cytotoxic enhancement, biological cooperation and temporal modulation. 
These strategies primarily aim to interfere with repair mechanisms and target distinct cell 
populations (e.g. hypoxic cells) and structures of the tumor microenvironment (vasculature).
1.5.1 Cell cycle specific radioenhancing mechanisms (cytotoxic enhancement)
It is known already for decades that radio-sensitivity of cells differs between cell cycle phases, 
that mitotic cells are the most radiosensitive and cell during S phase are the most resistant 
[20]. The first study to demonstrate that paclitaxel radio-sensitizes human astrocytoma cells 
to IR [146] was performed ten years after it became known that paclitaxel induces accumu-
lation of cells in M-phase [68]. Since then, several in vitro studies have demonstrated that 
taxanes enhance irradiation sensitivity by the accumulation of cells in the G2/M phase of 
the cell cycle [147-150]. Upon further investigations, it was shown that the radioenhancing 
mechanism based on the G2/M-block was dominant in paclitaxel-resistant tumors, where the 
arrested cells were not doomed to cell death by drug treatment alone and the M-phase arrest 
enhanced the cell-cycle specific sensitivity to subsequent IR [151-152]. Epothilones were also 
Figure 1.11. Representa-
ton of the nterplay between 
spatial cooperation, cytotoxic 
enhancement, biological coop-
eration, temporal modulation 
and normal tssue protecton. 
RT – radiotherapy, SF - surviv-
ing fraction, X – drug [145].
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probed for radiosensitizing properties. The semisynthetic epothilone B (BMS-247550) was 
evaluated in in vivo and in vitro settings for radioenhancing effects in human lung cancer cells 
and the mechanism of observed radioenhancement was attributed to the G2/M phase arrest 
[153]. 
The classical M-phase arrest-related mechanism of radio-sensitization by MTSAs was 
opposed by a study with patupilone performed by Hofstetter and co-workers [79]. In this 
study a very strong radiosensitizing effect of patupilone was observed at concentrations of 
the compound that induced not an M-phase arrest but accumulation in S phase instead. The 
authors speculated that a decelerated S phase transgression-related mechanisms could be respon-
sible for the observed radiosensitization. Interestingly, the radiation potentiating effect was 
also seen in non-proliferating ovarian carcinoma cell lines [150], again suggesting the existence 
of radioenhancing mechanisms different from the widely excepted M-phase-related radiosen-
sitivity.
1.5.2 Reoxygenation radioenhancing mechanisms (biological cooperation and 
temporal modulation)
The “tumor cell reoxygenation” theory (named by analogy with a classical radiobiological 
terminology) arose in an attempt to explain the time dependent radioenhancing effect of 
paclitaxel that was not correlating with M-phase accumulation of tumor cells [154]. The 
essence of the theory is that after exposure to the drug, the tumor oxygenation increases, 
which results in increased radiosensitivity. The tumor “reoxygenation” occurs as follows: 
after being treated with paclitaxel, the tumor experiences a massive cell loss due to apopto-
sis or necrosis [151, 155]. The cell loss reduces the overall oxygen consumption rate and 
previously hypoxic cells receive a better access to oxygen. The reoxygenation theory was 
supported by studies of Milas and co-workers, where they showed that paclitaxel had radio-
sensitizing effect on murin mammary carcinoma tumors only under air-breathing conditions 
but not under hypoxic conditions. In theses tumors, the pO2 was increased after paclitaxel 
treatment [156]. The “reoxygenation”-related radiation enhancement takes place in drug-sen-
sitive cell lines, whereas M phase-related mechanism occurs more prevalently in resistant 
cells or at lower doses of MTSAs [152].
1.5.3 Tumor microenvironment-related radioenhancing mechanisms (biological 
cooperation and temporal modulation)
The great potential of tumor microenvironment-directed properties of MTSAs has only re-
cently started to emerge, reflecting a better understanding of the importance of the tumor 
stroma for the treatment outcome. The studies that showed a higher radiosensitizing ability 
of patupilone in vivo than in vitro cell systems [79, 157]; they also indicated that the tumor 
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response to the combined treatment occurs not solely on the level of tumor cells.
Anti-angiogenic properties of MTSAs. As endothelial damage is fundamental for tu-
mor control, the radioenhancement by MTSAs may be due to their effect on the tumor endo-
thelial system [158]. The analysis of the emerging data shows that MTSAs can have both a 
direct and an indirect effect on tumor angiogenesis [159]. The direct effect can be attributed to 
inhibition of proliferation of endothelial cells and decrease of endothelial cell migration and 
capillary-like tube formation in vitro after treatment with MTSAs [88, 160-163]. 
The indirect anti-angiogenic effect is mediated by tumor cells, when the anti-neoplastic 
effect of MTSAs leads to depletion of tumor cell-secreted pro-angiogenic factors. This may 
happen by way of different mechanisms, including simple tumor cell loss, suppression of 
VEGF expression or secretion [164-165] and inhibition of HIF-1 expression and the con-
sequent decrease in HIF-dependent protein expression [166]. There is strong experimental 
evidence to suggest that the indirect effect on tumor vasculature is the most prevalent one. A 
decrease in microvessel density (MVD) after treatment with patupilone was only observed in 
patupilone-sensitive lung tumor xenografts but not in xenografts originated from patupilone-
resistant cells [157]. Moreover, the inhibition of HIF-1-dependent expression after patupilone 
treatment was only observed in drug-sensitive human ovarian cancer cells but not in their 
resistant counterparts [166]. 
The anti-angiogenic effect of MTSAs translates in the destruction of blood vessels and 
reduced MVD [157, 162, 167]. The decrease in MVD should lead to an increase of hypoxic 
regions within the tumor, which would reduce ability of IR to kill the tumor cells. However, 
the radioenhancement by MTSAs may be explained by a phenomenon known as “vasculature 
normalization” after anti-angiogenic treatment [168]. This effect is characterized by loss of 
only immature, non-functional vessels in the tumor, which improves oxygenation due to a bet-
ter perfusion of the remaining vasculature. As a result of vascular normalization, the decrease 
of MVD negatively correlates with tumor oxygenation [169]. However, it was demonstrated 
that the radioenhancing effect of the patupilone in lung tumor xenografts in mice can also be 
seen on the background of the compound-induced hypoxia in the tumor [157]. Patupilone is 
an equally potent anti-proliferative agent against normoxic and hypoxic cells. Therefore, the 
supra-additive anti-tumor effect of patupilone in this case may be a result of cooperative ac-
tion of multiple processes, including cell kill by radiation, by drug and by reduced oxygen and 
nutrition supply due to MVD reduction. 
Anti-metastatic properties of MTSAs. The potential role of radiotherapy in the induc-
tion of metastases was already discussed in detail above (see Chapter 1.2.2). In short, IR was 
shown to promote cell invasion in vitro and metastasis in vivo in mouse models [28-33]. This 
potentiating effect is most probably attributed to the ability of IR to induce the expression 
of MMPs (secreted proteinases that are required for cell invasion) [100, 102, 170-171]. The 
importance of MMPs for cancer progression and treatment response has only recently arisen 
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and has not yet been properly addressed in clinical research. However, there is increasing 
evidence that MMPs in tissue and plasma of cancer patients are upregulated after irradiation 
[142, 172]. 
MTSAs are very promising anti-metastatic agents. Multiple studies demonstrated that 
taxanes and epothilones can reduce migration of different cell types: smooth muscle cells [83] 
endothelial [81, 83, 88] and tumor cells (for example, ovarian and colon carcinoma) [86-87]. 
The anti-metastatic properties of paclitaxel and epothilones were also demonstrated in tumor-
bearing mice (for lung, prostate and breast tumors) [90-91, 93, 173]. 
The secretion of MMPs and TIMPs can also be targeted by MTSAs, as they are at least 
partially dependent on the dynamic functional MT system [113-114]. At low doses, paclitaxel 
impaires the secretion of MMP-2 and MMP-9 by human melanoma and prostate cancer cells, 
inhibiting cell invasion [48, 174]. One has to keep in mind, however, that the effect of MTSAs 
on MMP expression may be differential as paclitaxel enhanced MMP-2 and -9 expression in 
murine and human tumor cells, resulting in increased cell invasion [175-176]. 
MTSAs showed potency as anti-metastatic drugs in pre-clinical studies. These findings 
represent an additional rational for combining MTSAs with IR for cancer treatment. IR can 
induce MMP activity and this has to be taken in consideration during the radiation therapy 
regardless of metastasis induction risk, as during the last decade strong evidence arises that 
MMPs play an important role in cancer progression, not only for tumor dissemination but 
also in regulation of angiogenesis, cell survival etc. (see Chapter 1.4.3). MTSAs have a strong 
potential to inhibit cell invasion and MMP function, therefore a combination of these com-
pounds and IR for cancer treatment might be of great benefit.
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1.6 Aim of the study
The combined application of microtubule stabilizing agents (MTSAs) with ionizing radia-
tion is a highly promising treatment modality in cancer therapy [79, 153, 157]. Our own 
laboratory investigated the anti-tumor activity of the novel, clinically relevant MTSA 
patupilone (epothilone B). A strong supra-additive effect on the growth of several types of tu-
mor xenografts in mice was demonstrated when patupilone was administered in combination 
with IR [79]. Interestingly, the additive cytotoxic effect of patupilone and IR was much less 
pronounced in vitro, indicating that an additional mechanism on the level of the tumor micro-
environment (TME) may contribute to the supra-additive in vivo response. Further investiga-
tions revealed that this supra-additive anti-tumor effect of patupilone and IR in vivo can only 
be observed in tumors derived from patupilone-sensitive cancer cells [157]. This suggests 
that the effect on the TME may be an indirect effect mediated by cancer cells, perhaps via 
the secretion of active molecules. Matrix metalloproteinases (MMPs) and tissue inhibitors of 
MMPs (TIMPs) are important components of the TME, which are secreted both by tumor-
associated stromal cells and by cancer cells. The overexpression of MMPs and TIMPs was 
reported for almost all tumor types and associated with inferior survival prognosis [132, 139]. 
Furthermore, MMPs are upregulated after IR and can contribute to IR-induced tumor aggres-
siveness [33]. As secretion of MMPs at least partially depends on the microtubule system [48, 
113], MTSAs are potential inhibitors of MMP functions.
The goal of the present study was to investigate in vitro whether the MTSA patupilone 
influences the function of MMPs in IR-treated human tumor cells. To approach the question 
we defined the following aims: 1) to assess the changes in the activity of secreted MMPs after 
irradiation and the effect of patupilone treatment on these changes; 2) to evaluate the biological 
relevance of the treatment-altered MMP activity in functional cell invasion assay; 3) to investigate 
the mechanisms underlying the observed MMP activity alterations on different levels of the 
MMP regulatory cascade.
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2 Materials and Methods
2.1 Cell lines and preparation of conditioned cell culture media
All cells (Table 2.1) were grown at 37° C in a 5 % CO2 humidified atmosphere. Conditioned 
cell culture media (CM) was prepared as follows: after indicated treatment cells were main-
tained in serum-free Ultraculture medium (Lonza, Fischer Scientific) for 24 h. The cell cul-
ture medium was collected, centrifuged at 10’000x g for 5 min at 4° C and the supernatants 
were stored at -80° C. CM from HCT116 and U251 cells were concentrated using Amicon 
Ultra centrifuge concentrators Ultracel-5k (Millipore) 10-15-fold and 4-5-fold, respectively.
Table 2.1. Human cell lines and cell culture media.
Cell line Description Basal medium Additives
HT1080
ATCC No CCL-121
fibrosarcoma 
cells, (a gift of 
Prof. B. Oder-
matt, University 
of Zurich)
IMDM
10 % (v/v) fetal 
bovine serum, 
1 % (v/v) penicil-
lin-streptomycin
HCT116
ATCC No CCL-247
Human colon 
carcinoma cells RPMI 10 % (v/v) fetal bovine serum, 
1 % (v/v) peni-
cillin-streptomy-
cin and 1 % (v/v) 
L-glutamine.
U251
glioma cells, 
(a gift of Prof. 
K.Frei University 
of Zurich)
DMEM
DAOY
ATCC No HTB-186
 medulloblastoma 
cells Improved MEM
10 % (v/v) fetal 
bovine serum, 
1 % (v/v) penicil-
lin-streptomycin
D341 
ATCC No HTB-187
medulloblastoma 
cells Improved MEM 10 % (v/v) fetal bovine serum, 
1 % (v/v) penicil-
lin-streptomycin, 
1 % NAAA
D425
medulloblastoma 
cells Improved MEM
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2.2 Reagents and Antibodies
Reagents and Antibodies (ABs) Manufacturer
Alamar Blue Biosource Int.
All cell culture media and supplements Gibco, Invitrogen
anti-MMP-14 AB, rabbit polyclonal Abcam
anti-MMP-3 AB, mouse monoclonal Santa Cruz Biotechnology, Inc.
anti-MMP-9 AB, rabbit monoclonal Abcam
anti-TIMP-1 AB, neutralizing, goat R&D Systems
anti-TIMP-2 AB, neutralizing, goat R&D Systems
anti-β-actine AB, mouse monoclonal Sigma
anti-β-tubulin AB, mouse monoclonal BD Pharmigen
APMA (4-aminophenylmercuric acetate) AnaSpec
Control goat IgG Sigma
Fast SYBR® Green Master Mix Applied Biosystems
LipofectamineTM 2000 Invitrogen
MatrigelTM BD
NNGH 
(N-Isobutyl-N-(4-methoxyphenylsulfonyl) glycyl hydroxamic 
acid)   
Calbiochem®
ProLong® Gold Antifade Reagent Invitrogen
RNAse A Quigen
secondary anti-goat AB, donkey, HRP-linked Santa Cruz Biotechnology, Inc.
secondary anti-mouse AB, from goat, AlexaFluor®488-linked Molecular Probes®, Invitrogen
secondary anti-mouse AB, from sheep, HRP-linked GE Helthcare
secondary anti-rabbit AB, from donkey, HRP-linked GE Helthcare
SensoLyteTM 520 Generic MMP-2 assay kit AnaSpec
All other chemical reagents Sigma-Aldrich®
2.3 Irradiation and Patupilone
Irradiation was performed at room temperature using a Gulmay Xstrahl 200 kV X-ray unit at 
1 Gy/min. Patupilone (epothilone B, EPO906) was provided by Novartis Pharma AG (Basel, 
Switzerland). Patupilone was dissolved in DMSO as 1 mM stock solution and stored at -20° C. 
For the experiments, it was further diluted in the corresponding cell culture media. For each 
experiment, fresh dilutions were prepared.
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2.4 Proliferation assay
Cell proliferation was assessed using the 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazo-
lium bromide (MTT)-like Alamar Blue (Biosource Int.) colorimetric assay according to 
manufacture’s instructions. Absorption at 570/670 nm was measured with an Ultra Micro-
plate Recorder (Bio-Tech Instruments Inc.). Cells were seeded in 96-well plates and treated 
with increasing concentrations of patupilone 24 h prior to irradiation with increasing doses 
of IR. Proliferative activity was measured daily for 72 h after IR. All measurements were 
performed in triplicate in at least 3 independent experiments.
2.5 Clonogenic assay
The amount of plated cells was adjusted to obtain ~100 colonies per cell culture dish with a 
given treatment. 24 hours after plating cells were treated with increasing concentrations of 
patupilone and irradiated 24 h later. Colonies were allowed to grow under normal cell 
culture conditions for 7-10 days before fixation with Methanol/Acetic acid (75 %/25 %, v/v) 
and staining with 2% crystal violet. Colonies with more than 50 cells were counted manually. 
The surviving fraction (SF) with a given treatment was determined as follows: SF = (amount 
of counted colonies) / (amount of seeded cells x PE), where PE is a plating efficiency of 
untreated cells: PE = (amount of counted colonies) / (amount of seeded cells). For the deter-
mination of the synergistic effect, the earlier described model of synergy was used [177] and 
the following equation was applied: D = (SF(treatment 1) x SF(treatment 2)) / SF(treatment 
1+2). When D > 1, treatments were considered to have a synergistic effect,  when D = 1 – an 
additive effect and D < 1 – a less than additive effect. 
2.6 Cell cycle distribution analysis
Cell cycle distribution was determined by analysis of DNA content in cells by Flow cytometry. 
Cells were grown under normal cell culture conditions with different treatments applied. 
Then cells were trypsinized, washed with PBS and fixed with 70 % ethanol and stained 
with propidium iodide (50 μg/mL, containing 14 kU/mL RNAse A). The cells were analyzed 
on FACS Canto flow cytometer (BD Biosciences). Cell cycle analysis was performed using 
FlowJo 7 software (Tree Star Inc) by applying Dean-Jett-Fox model.
2.7 MMP activity assay
MMP activity in non-activated CM was determined using a FRET-based MMP-2 activity 
assay (SensoLyte MMP-2 assay kit, AnaSpec). Even though – according to the kit de-
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scription – this assay is designed for the measurement of specific MMP-2 activity, the used 
peptide substrate can be cleaved by multiple MMPs in CM. Therefore we did not consider 
it to be specific for MMP-2 and used it for the determination of pooled MMP activity. The 
substrate cleavage reaction was performed according to the manufacture’s instructions. In 
order to determine membrane-bound MMP activity, cells were washed twice with fresh serum-
free media and incubated with the FRET assay substrate. The fluorescent signal was measured 
in a Tecan GENios spectrophotometer at 31° C every hour for 14 hours. The acquired signal 
was adjusted to the cell number and presented as the initial velocity of the substrate cleavage 
reaction (V0), relative to control. V0 was determined as a slope of the curve – the fluorescent 
signal plotted versus time – using linear regression (GraphPad Software, Inc).  
2.8 Cell migration assay
Transwell inserts (6.5 mm, 8 µm pores, Costar) were either coated with MatrigelTM (BD) for 
the cell invasion assay or left uncoated for the cell motility assay. Complete cell culture media 
with 10 % FCS was used as an attractant for migrating cells. For HCT116 cells, the attractant 
was a mixture of complete cell culture medium (with 10 % FCS and penicillin/streptomycin) 
and 48 h conditioned media from HCT1116 (5:1) cells. 5’000 cells/insert for HT1080 cells, 
8’000 cells/insert for U251 cell and 50’000 cell/insert for HCT116 cells were seeded in 200 μL 
of serum-free media. Patupilone was added to cells at the moment of seeding and cells were 
irradiated 4 h thereafter. Cells were allowed to migrate for 24 h. For quantification, cells from 
the upper side of the insert were scraped away; and inserts were fixed in Methanol/Acetic acid 
(75 %/25 %, v/v) and stained with DAPI. The invaded cells were counted manually under 
the microscope or using the software (Imaris, Bitplane). Each experiment was carried out in 
quadruplicates.
Coating with Matrigel (BD) was performed as follows: 50 μL of Matrigel, diluted 1:20 
with DMEM cell culture medium, was added per insert and dried overnight at RT under sterile 
flow. On the day of experiment, inserts were rehydrated with serum-free media for 4 h at 37° C.
2.9 qRT-PCR
Total mRNA was isolated with RNeasy Plus Mini Kit (Qiagen). Reverse transcriptase reac-
tion was conducted with 1 μg of mRNA with High capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). qRT-PCR was performed with Fast SYBR Green Master Mix (Applied 
Biosystems) on 7900H PCR Instrument (Applied Biosystems). Data was analysed using 
RQ-manager software (Applied Biosystems), employing the ΔΔCt method. The primers were 
a generous gift from Professor S. Gay (University Hospital Zurich).
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Primers 5’-3’
MMP-1 F: TGT GGA CCA TGC CAT TGA GAA
R: TCT GCT TGA CCC TCA GAG ACC
MMP-2 F: CTT CCG TCT GTC CCA GGA T
R: CCC CAT AGA GCT CCT GAA TG
MMP-3 F: GGG CCA TCA GAG GAA ATG
R: CAC GGT TGG AGG GAA ACC TA
MMP-9 F: GGC CAC TAC TGT GCC TTT GAG
R: GAT GGC GTC GAA GAT GTT CAC
MMP-14 F: TGG AGG AGA CAC CCA CTT TGA
R: GCC ACC AGG AAG ATG TCA TTT C
TIMP-1 F: AGT GGC ACT CAT TGC TTG TG
R: TTT TCA GAG CCT TGG AGG AG
TIMP-2 F: TTT TGC AAT GCA GAT GTA GTG AT
R: TCC TTC TCA CTG ACC GCT TT
TIMP-3 F: ACG CTG GTC TAC ACC ATC AAG
R: TTG GTG AAG CCT CGG TAC A
18srRNA F: ATG GCC GTT CTT AGT TGG TG
R: CGC TGA GCC AGT CAG TGT AG
TBP F: CGG CTG TTT AAC TTC GCT TC
R: TTC TTG GCA AAC CAG AAA CC
2.10 Western Blot
The cell lysates were collected by suspending cells in the Laemmli buffer and CM was mixed 
with 5x Laemmli buffer. Samples were boiled at 95° C for 5 min and subjected to 12 % 
SDS-PAGE, followed by blotting onto PVDF-membranes using a semi-dry system (Hoefer). 
Detection was performed using a chemiluminescence detection system (ECL Western Blotting 
detection system, Amersham, GE Healthcare). Western blots were quantified by Quantity One 
4.6 software (Bio-Rad Laboratories). The following antibodies were used: anti-TIMP-1 and 
TIMP-2 (neutralizing antibodies, R&D systems), anti-MMP-3 (SantaCruz Biotechnology, 
INC.), anti-MMP-9 and -14 (Abcam) and anti-β-actin (Sigma).
2.11 Gelatinolytic zymography assay
For the determination of gelatinolytic activity, CM samples were mixed with 5x Laemmli 
buffer without β-mercaptoethanol and loaded on 10 % SDS-PAGE, containing 1 mg/mL gela-
tin (running conditions: 20 mA per gel, 2.5 h, at 4° C). Then, the gels were washed in 2 % 
Triton X-100 and incubated in TCN buffer (Tris HCl pH 7.4, 50 mM, NaCl 0.2 M, CaCl2 5 mM) 
for 36 h. Gels were stained with 0.2 % Coomassie Blue until transparent bands could be 
visualized against a dark blue background.
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2.12 MMP antibody array
Protein levels of MMP-1, -2, -3, -8, -9, -13 and TIMP-1, -2, -4 were determined in CM using an 
anti-Human MMP antibody array (RayBiothec). The antibody array was performed according 
to the manufacturer’s instructions. The array membranes were developed using an Amer-
sham western blot film and developed films were scanned and quantified with QuantityOne 
quantification software (BioRad Laboratories). Values were adjusted to the cell amount and 
presented relatively to the control. At least two independent experiments were performed for 
each treatment condition.
2.13 Transfection with siRNA and cDNA constructs
Transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. siRNAs for downregulation of human TIMP-1 (GenBank BC000866.1) 
and human TIMP-2 (GenBank BC052605.1) were synthesized by Mycrosinth (Switzerland). 
Two different sequences of siRNA were randomly used in the experiments to exclude 
unspecific RNA interference effects. siRNA against firefly luciferase was used for control 
transfection. siRNA sequences (5’-3’):
siTIMP-1#1 GAU GUA UAA AGG GUU CCA AdTdT [178]
siTIMP-1#2 GAU GAC CAA GAU GUA UAA AdTdT (designed, Microsynth siRNA Design Tool)
siTIMP-2#1 GGC ACA UUA UGU AAA CAU AdTdT [178]
siTIMP-2#2 GCA GAU AAA GAU GUU CAA AdTdT (designed, Microsynth siRNA Design Tool)
siLuc CGT ACG CGG AAT ACT TCG AdTdT (Microsynth).
pEYFP-TIMP-1 and pECFP-MMP-9 were generous gifts of Dr. M. Roderfeld (Justus 
Liebig University Giessen). pEGFP (a discontinued product of  Clontech) was generously 
donated by B. Malevich (University of Zurich). TIMP-1 and MMP-9 were subcloned into the 
EGFP vector to obtain pEGFP-TIMP-1 and pEGFP-MMP-9.
2.14 Microscopy
For wide-field and confocal fluorescent microscopy staining procedure were as follows: 
cells were cultured on glass cover slips for microscopy, washed with PBS, fixed with 4 % 
formaldehyde 20 min at RT, permeabilized with 90 % methanol 5 min at RT and blocked in 
3 % FCS in PBS for 30min at RT. Incubation with primary antibodies was for 1 h at RT and 
with secondary fluorofore-conjugated antibodies for 40 min at RT in the dark. Stained cover 
slips were fixed one more time with 4 % formaldehyde for 10 min at RT and then mounted 
on glass microscopy slides (Menzel Gläser SuperFrost) with ProLong® Gold Antifade Re-
agent (Invitrogen). Slides were examined with Leica SP5 confocal microscope or with Zeiss 
Axiovert 25 microscope equipped with AxioCam MRm (Zeiss) camera.
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2.15 Statistical analysis
Statistical analysis was performed using GraphPad Prism 3-5 software (GraphPad Software, 
Inc.). A comparison between the groups was performed using t-test, the level of significance 
was set at P<0.05.
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3 Results
3.1 Cytotoxic effects of patupilone and ionizing radiation, applied            
      alone and in combination
3.1.1 Treatment with patupilone and ionizing radiation has an additive                              
inhibitory effect on cell proliferation
To assess the effect of patupilone and IR on cell proliferation, an MTT-like assay based on the 
detection of cellular metabolic activity was performed. HT1080 human fibrosarcoma, U251 
human glioma and HCT116 human colon carcinoma cells were treated with increasing doses 
of patupilone and ionizing radiation. All 3 tested cell lines displayed average sensitivity to 
patupilone in a low nanomolar range, with an IC50 being approximately 0.4 nM for HT1080 
and U251 cells and 1.5 nM for HCT116 cells (Fig. 3.1). The radiosensitivity of the tested cell 
lines differed to a greater extent. HT1080 cells were the most radioresistant. Even a dose of 10 Gy 
did not inhibit proliferation of these cells by more than 30 %. An IC50 of approximately 5 Gy 
could be determined for the more radiation sensitive U251 and HCT116 tumor cells.
Treatment with patupilone and IR has an additive effect on tumor cell proliferation as 
demonstrated in several studies [79, 157]. As such, we tested whether a combined treatment 
with patupilone and IR also has an additive anti-proliferative effect in our cell systems 
(Fig. 3.1, bottom). Cells were pre-treated with patupilone for 24 h prior to irradiation. In all 
three cell lines, an additive anti-proliferative effect was observed with patupilone already at 
very low concentrations, far below IC
50
. This was observed in HT1080 cells after treatment 
with 0.2 nM and 2 or 10 Gy of IR, in U251 cells after treatment with 0.25 nM of patupilone 
and 2 Gy of IR, and, very prominently, in HCT116 cells after combined treatment with 1 nM 
patupilone and 2 Gy of IR (Fig. 3.1, bottom).
3.1.2 Patupilone and ionizing radiation have a supra-additive inhibitory effect         
on clonogenic cell survival
To characterize the long-term effect of patupilone and IR on cell growth, clonogenic cell 
survival assays were performed with HT1080, U251, HCT116, DAOY, D425 and D341 cells 
(DAOY, D425 and D341 are human medulloblastoma cell lines). In terms of cell sensitivity 
to IR and patupilone, results of the clonogenic assays correlated with the results of the cell 
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Figure 3.1. Cell prolferaton after treatment wth the ncreasng concentratons of patuplone and the ncreasng 
doses of IR. In case of the combned treatment the human tumor cells were treated wth patuplone 24 h pror to 
IR. Mean +/- SD, representative assays from at least 3 independent experiments are shown.
proliferation assays described above (Fig. 3.1). HT1080 cells were most radioresistant as ir-
radiation with 2 Gy had no effect on clonogenic survival and the survival fraction after 10 Gy 
of IR was still 0.3 (Fig. 3.2). In these cells, 0.2 nM patupilone had almost no effect on cell 
clonogenicity. Likewise, U251 and HCT116 cells were resistant to treatment with 0.05 nM 
and 0.5 nM of the compound, respectively. DAOY and D425 medulloblastoma cells were 
highly sensitive to patupilone. Clonogenic survival of these cells was reduced to almost 1 % 
after treatment with picomolar (60-80 pM) concentrations of patupilone.
The radiosensitizing effect of patupilone (defined as supra-additive effect on cell survival 
after treatment with the compound and IR) was pronounced when determined on the level of 
cell clonogenicity (Fig. 3.2). A supra-additive inhibitory effect on clonogenic cell survival 
was observed in the fiborsarcoma cell line when patupilone was combined with 10 Gy of IR 
(D (factor of synergy) = 2-9.8 for 0.1-0.8 nM, respectively). In U251 cells and HCT116 cells, 
a supra-additive effect was observed with 0.2-0.6 nM and 0.5-1 nM patupilone, respectively, 
applied in combination with 2 and 4 Gy. In these two cells lines, the treatment with the highest 
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tested concentrations of patupilone applied in combination with 4 Gy IR resulted in D = 1.5 
and 3.6 for U251 and HCT116 cells, respectively. Combined treatment reduced clonogenicity 
in all medulloblastoma cell lines in an at least additive way. Patupilone exhibited a very strong 
radioenhancing effect (with max D = 1000) in D341 medulloblastoma cells at concentrations 
below 1 nM when applied together with 4 Gy IR.
3.1.3 Low concentrations of microtubule inhibitors did not affect morphology        
of microtubule cytoskeleton
The mechanisms of cytotoxicity of MTSAs are dose-dependent. At high doses, MTSAs pre-
vent depolymerisation of MT. Morphologically, it manifests by occurrence of MT-bundles in 
the cytoplasm and leads to abrogation of mitosis due to prevention of spindle formation. After 
treatment with lower doses of MTSAs, cytoskeletal structures retain normal morphology; 
however, MT dynamics (the rate of growth and shortening) can be inhibited and cells may 
lose clonogenicity as a result of aberrant mitotic divisions [61, 68-69]. Therefore, microscopic 
evaluation of MT structures in the cell provides the first clues for the mechanism of action of 
MTSAs.
The morphology of the microtubule cytoskeleton of HT1080 cells was assessed by 
fluorescent microscopy. The HT1080 cells were chosen for the experiment as they are a 
well-established in vitro system for studies of MMP function and cell invasion and most 
Figure 3.2. Supra-addtve ant-clonogenc effect of patuplone admnstered n combnaton wth IR. The conogenc 
survval was determned after treatment wth the ncreasng doses of patuplone appled 24 h before rradaton. 
Mean +/- SE, n=3.
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Figure 3.3. The MT morphology in HT1080 cells after treatment with MT-interfering agents. 24 h and 48 h after 
treatment with 0.2 and 2 nM patupilone, respectively; 14 h after nocodazole treatment; 24 h after taxol treat-
ment. The MT bundling occurs with 100 nM paclitaxel. The MT disruption occurs with 20 ng/mL nocodazole. 
Green – β-tubulin, blue – DAPI, scale bar 10 μm.
of following work was performed with this cell line. The cells were treated with different 
concentrations of patupilone and other MT-inhibitors, such as paclitaxel and nocodazole (MT 
destabilizer). A classical microtubule bundle formation was observed after 24 h treatment 
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with 100 nM paclitaxel and, to a lower extent, after incubation of cells with 2 nM 
patupilone (Fig. 3.3). Treatment with lower doses of patupilone and paclitaxel did not lead 
to changes in MT morphology. No changes were observed after treatment with 1 ng/mL 
(non-toxic concentration) of nocodazole, in comparison to the response to a higher cytotoxic 
concentration (20 ng/ml), which led to a complete disruption of the MT in the cells.
Our laboratory previously demonstrated that patupilone is a potent radio-
sensitizer in vitro and in vivo in different human cancer cell systems [79, 
157]. The results presented herein further confirmed the ability of patupilone 
to enhance IR-induced cytotoxicity (Fig. 3.2). Of additional interest, is the 
fact that patupilone has a radiosensitizing capacity at very low doses that 
are not cyctotoxic themselves and do not alter the MT cytoskeleton structure 
(0.2 nM patupilone in HT1080 cells, Fig. 3.3).
3.2 Patupilone counteracts ionizing radiation-dependent                                              
      enhancement of MMP function
3.2.1 Patupilone inhibits ionizing radiation-induced MMP activity in           
conditioned cell culture media 
The enzymatic activity of MMPs is essential for their role in a vast majority of pro-tumorigenic 
processes. The repertoire of MMP substrates extends beyond growth factors, regulatory proteins 
and protein components of the extracellular matrix (ECM). By cleaving their substrates, 
MMPs can regulate nearly all stages of tumor development, including, for example, cell 
growth and apoptosis, angiogenesis and metastasis (see Chapter 1.4.5). Moreover, there 
is strong evidence that IR can promote MMP expression (see Chapter 1.2.2) and, therefore, 
tumor aggressiveness. As radiation therapy is one of the most prevalent cancer treatment 
modalities, it is important to take into consideration its potentially unfavourable effects, such 
as the induction of MMPs. Combination therapies aimed at counteracting these unfavourable 
effects are therefore of a substantial interest. MTSAs are potential candidates for such a com-
bination, as they can inhibit MMP secretion [48, 174]. 
Herein, we probed the influence of patupilone and IR treatment on MMP activity. As 
MMPs are secreted proteins and enzymaticaly active in the extracellular space, we used a 
FRET-peptide based assay to determine MMP activity in conditioned cell culture media 
(CM). The assay is not specific for individual MMP activity but allows to measure pooled 
MMP activity without pre-processing the sample. The determination of the “native” activity 
of secreted MMPs is important as it can be translated directly in most of MMP biological 
functions [139].
MMP activity was assessed in CM of HT1080, U251 and HCT116 cells after treatment 
with IR and patupilone, alone and in combination (Fig. 3.4). IR increased MMP activity in 
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Figure 3.4. Patuplone at the  non-
cytotoxc concentraton nhbts the 
MMP actvty nduced by IR n the 
cell culture meda supernatant. The 
cells were treated wth the ndcated 
concentratons of patuplone 24 h 
pror to IR or 2 nM of patuplone 
1 h after IR, the MMP activity was 
measured 24 h after IR treatment. 
The results are plotted as mean +/- 
SE. N=13 for HT1080 cells, n=6 for 
U251 cells, n≥4 for HCT116 cells, 
*P<0.05, **P<0.01, ***P<0.001.
CM, determined 24 h after irradiation, in a dose dependent manner in all three cell systems 
tested. The highest dose of IR, which was used in our experimental setup, decreased the 
amount of cells by 30-40 %; as such, the measured MMP activity was corrected to the cell 
number. We observed a 1.9 and 1.8-fold increase of MMP activity in CM of HT1080 and 
U251 cells after irradiation with 10 Gy and 4 Gy, respectively (P>0.001). A 1.5-fold increase 
of MMP-activity was detected in CM of HCT116 cells after irradiation with 5 Gy (P>0.001). 
An increase of MMP activity in CM of all three cell lines was also observed after treatment 
with cytotoxic doses of patupilone (higher than 2 nM, data not shown).
Treatment with patupilone at low doses (doses that did not lead to significant decrease of 
cell proliferation and clonogenic survival: 0.2 nM for HT1080 cells, 0.05 nM for U251 cells 
and 0.5 nM for HCT116 cells) had various effects on MMP activity. In HT1080 cells the MMP 
activity was reduced by 5 % (P=0.011). In U251 cells MMP activity was increased by 15 % 
(P=0.004). No effect on MMP activity after treatment with low dose patupilone was observed 
in HCT116 cells (Fig. 3.4). Thus the influence of patupilone treatment on basal level of MMP 
activity was minimal. A more pronounced effect of patupilone was observed on the IR-induced 
MMP activity levels. MMP activity in U251 cells was elevated 1.4- and 1.8-fold after irradiation 
with 2 and 4 Gy respectively. Pre-treatment with 0.05 nM of patupilone completely abrogated 
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IR-induced MMP activity in these cells (P=0.0037, Fig. 3.4). Pre-treatment of HT1080 cells 
with 0.2 nM of patupilone diminished irradiation-induced elevation of the MMP activity to 
1.5-fold, compared to an almost 2-fold increase after IR treatment alone (P<0.0001). A similar 
tendency was determined in HCT116 cells, even though MMP activity was not significantly 
decreased after combined treatment with 5 Gy and 0.5 nM patupilone, compared to irradiation 
treatment alone.
Patupilone accumulates in cells during long-term incubation [60]. This pharmacodynamic 
feature can lead to the following phenomena: a longer incubation with low dose of the 
compound leads to the same biological outcome as a shorter incubation with a higher dose. 
To probe our results observed in HT1080 cells after treatment with 0.2 nM patupilone for 
24 h prior to IR, we performed a similar experiment with 10-fold higher concentrations of 
patupilone (2 nM). The high concentration of the compound was applied immediately after 
irradiation (no pre-incubation) and MMP activity was assessed in 24 h. During such a short 
experimental time, incubation with 2 nM patupilone did not lead to cytotoxicity or a decrease 
in the cell number. In this experimental setup, we again observed patupilone counteracting 
IR-induced MMP activity elevation in CM (Fig. 3.4). The MMP activity was elevated only 
1.5-fold after combined treatment with 10Gy and 2 nM, compared to almost 2-fold increase 
after IR treatment alone (P=0.0008).
3.2.2 Patupilone and ionizing radiation do not influence membrane-bound 
MMP activity
The MMPs can be anchored to the outer cell membrane. First, there are membrane type 
MMPs (MT-MMPs) which are trans-membrane proteins. Second, secreted MMPs may be 
attached to the cell membrane through various receptors on the cell surface. The MMPs on 
the outer cell surface are relevant for pro-MMP activation and for the cell migration as they 
Figure 3.5. Patuplone and IR have no effect on the 
membrane-bound MMP activity. HT1080 cells were treated 
with patupilone and IR as indicated in Fig. 3.4 or with 10 
μM of NNGH. The results are plotted as mean +/- SE, 
n=5, ***P<0.001.
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can degrade ECM (rev in  [96]). We therefore assessed membrane-bound MMP activity after 
treatment with 0.2 nM patupilone and 10 Gy by exposing HT1080 cells to the FRET MMP 
substrate that was well tolerated by the cells. The rate of substrate cleavage activity measured 
in this experimental setup was 20-fold higher than in CM. The measured signal was attributed 
to MMP activity as it could be completely abolished by the specific MMP inhibitor NNGH 
(N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid) (Fig. 3.5).
No change in cell-associated MMP activity could be determined after treatment with 
patupilone and IR, indicating that only protease activity, derived from secreted MMPs, is 
affected by the investigated treatment modalities.
3.2.3 Effect of microtubule inhibitors on ionizing radiation-induced MMP     
activity in conditioned cell culture media
We hypothesized that the counteracting effect of patupilone on IR-induced MMP activity may 
be due to its ability to inhibit the MT function. If MT-inhibitory properties of the compound 
play an important role, then other MT inhibitors should demonstrate a similar counteracting 
effect on IR-induced MMP activity. Therefore, we tested the ability of the clinically relevant 
MT stabilizer paclitaxel and two MT destabilizers, vincristine and nocodazole, to inhibit IR-
induced MMP activity in CM of HT1080 cells. 
Paclitaxel, at a concentration of 10 nM, strongly reduced the basal MMP activity 
level (by 40 %) and decreased IR-induced MMP activity to basal level (Fig. 3.6, left). 
Increasing concentrations of vincristine were tested but we could not determine any effect 
of low concentrations of the compound on MMP activity in CM of HT1080 cells. Vincristin 
Figure 3.6. Mcrotubule nhbtors dmnsh the IR-nduced ncrease of the MMP actvty n the cell culture meda 
supernatant. HT1080 cells were treated with (A) 10 nM paclitaxel (Pac) after IR, the results are plotted as mean 
+/- SE, n=2;  or (B) 1 ng/mL nocodazol after IR for 4 (circles) or 14 (squares) hours. The MMP activity was 
measured 24 h after IR. *P<0.05.
A B
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at higher concentrations upregulated MMP activity (data not shown). On the other hand, 
enhancement of MMP activity by IR was diminished when cells were treated with another 
MT destabilizer nocodazole. This effect was small, but significant (P=0.026, Fig. 3.6, right). 
Thus MT stabilizers might have a more pronounced inhibitory effect on MMP activity in CM 
than MT destabilizers. Importantly, even very high concentrations of patupilone (100 nM) did 
not inhibit the activity of purified recombinant MMP-2 and -3 (data not shown). Therefore, 
the observed inhibition of MMP activity in CM after patupilone treatment has to be attributed 
to cellular processes.
3.2.4 Differential effects of patupilone and ionizing radiation on cell motility 
and invasion
We demonstrated that patupilone and IR variously altered MMP activity levels in CM. 
Furthermore, patupilone, at a low non-cytotoxic concentration, can counteract IR-induced 
MMP activity. The question remains whether the observed effect is of a biological relevance. 
To test this, we assessed the cell invasion in a transwell chamber assay after corresponding 
treatments. The cell invasion does not reflect all the complexity of MMP functions because 
the MMPs play a role in the regulation of many other cellular processes, including apopto-
sis, angiogenesis and so forth [179]. However, the transmigration assay is highly specific for 
MMPs as it requires extracellular matrix (ECM) degradation [180]. In addition to the ECM 
proteolysis, a certain level of cell motility is required for successful cell invasion.
Transwell chamber assays were performed with HT1080, U251 and HCT116 cells to 
assess their migration capacity after treatment with patupilone and IR. To mimic a process 
of tumor cell invasion through the basal membrane, MatrigelTM-coated transwell inserts 
were used. Cell motility was evaluated in non-coated inserts. The three tested cell lines were 
different in their basal rate of migration (see Table 3).
Table 3. Migration and invasion capacity of human tumor cells.
Cell line Cells migrated through the pores 
of the transwell insert in 24h
Cells invaded through MatrigelTM 
in 24h
HT1080 100% 10-20%
U251 20% 1-5%
HCT116 ~1% <0.1%
The migration capacity of the cells was tested after treatment with increasing concentrations 
of patupilone and dosed of IR. Patupilone at non-antiproliferative concentrations (see above, 
Fig. 3.1, 3.2) (< 0.2 nM; 0.025 nM and 0.1 nM) and low doses of IR (2 Gy; 1 Gy and 2 Gy) 
did not affect the motility of the HT1080, U251 and HCT116 cells, respectively (Fig. 3.7). 
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Treatment with higher concentrations of patupilone, as well as higher doses of IR, inhibited 
cell motility by up to 50 % in all three cell systems in a dose dependent way. High doses of 
patupilone and IR, which inhibited cell motility, also resulted in decreased rates of invasion. 
The low dose IR, on the contrary, increased cell invasion in HT1080 cells by approximately 
30 %, even though cell motility was slightly decreased. In U251 cells, invasion after irradiation 
Figure 3.7. Patuplone and IR have varous dose-dependent effects on the cell motlty and nvason. The cell 
invasion and motility was assessed in the transwell assay 24 h after the indicated treatments. Bars and the left 
Y-axis - the percentage of the motile/invading cells relative to control, mean +/- SE, N>3, *P<0.05, **P<0.01, 
***P<0.001. The dashed line and the right Y-axis – the amount of viable cells determined under the same 
condtons.
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with 2 Gy was similar to control but cell motility at this dose was reduced by almost 30 %. 
Interestingly, the invasion of HT1080 and HCT116 cells was already inhibited by patupilone 
at a concentration that did not have any effect on cell motility or viability, namely 0.1 nM. This 
effect cannot be due to reduced cell motility and therefore might be attributed to a decreased 
ability of the cells to degrade extracellular matrix. 
The cell migration capacity under different conditions was determined within 24 hours. In 
such a short experimental time, no quantitative changes with regard to cell viability occurred 
after treatment with patupilone at tested concentrations (≤ 2 nM for HT1080 and HCT116 
cells and  ≤ 0.5 nM for U251 cells). After treatment with IR (dose of 2 Gy and more), the 
number of HT1080 and U251 cells decreased in a dose dependent way, most probably due to 
IR-induced cell cycle arrest, since the amount of dead cells in the trypan blue viability assay 
was negligible. Thus, the observed decrease in cell motility after irradiation, as determined in 
the transwell chamber assay, could result from a decreased amount of cells.
3.2.5 Patupilone inhibits ionizing radiation-induced tumor cell                     
 “invasive capacity“
As described above, low dose IR inhibited cell motility. However, cell invasion was not 
decreased in U251 cells and even promoted in HT1080 cells. To further analyse our results, 
we determined the “invasive capacity” of the cells, which was defined as follows: (amount of 
invading cells) / (amount of motile cells). This approach allowed us to focus on motility-
independent rates of cell invasion given by the ability of the cells to degrade the MatrigelTM. 
This analysis revealed that treatment with low dose IR (2 Gy), resulted in an increase of 
invasive capacity by 50 and 30 % for HT1080 and U251 cells, respectively (Fig. 3.8). 
Pre-treatment of cells with patupilone completely abolished IR-induced invasion, and cells 
that had been treated with a combination of patupilone and IR exhibited the same invasive 
capacity as untreated control cells. The treatment of cells with patupilone alone led to a slight 
Figure 3.8. Patuplone coun-
teracts the IR-dependent nduc-
ton of cell nvason. The cells were 
plated n the transwell nserts n 
the presence of the ndcated 
concentratons of patuplone 
4 h pror to rradaton. The rate 
of nvason was evaluated 24 h 
after platng. The results are 
plotted as percentage of the n-
vading cells relative to control, 
mean +/- SE, n≥3, *P<0.05, 
**P<0.01, ***P<0.001.
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decrease of the basal cell invasion in HT1080 cells.
Overall the effects of IR and patupilone on cell invasion were well correlated with the 
effects of the corresponding treatments on MMP activity in CM (Fig. 3.4). Both on the level 
of MMP activity and cell invasion, the following results were observed: a decrease of MMP 
activity and cell invasive capacity after treatment with patupilone alone (in case of HT1080 
cells), an increase after irradiation and the counter effect of patupilone on IR-induced MMP 
activity and cell invasion.
3.2.6 MMP enzymatic activity is required for cell invasion
As outlined, we observed a correlation between the changes in the invasive capacity of tumor 
cells and MMP activity in their CM, in response to the different treatment modalities (IR and 
patupilone, alone and in combination). In order to mechanistically link these processes we 
performed transwell invasion experiments in the presence of MMP inhibitors: recombinant 
TIMP-1 and -2 (rTIMP-1, rTIMP-2, natural non-cell permeable inhibitors of MMPs) and a 
small molecule cell-permeable MMP-specific inhibitor NNGH.
First, the efficacy of the inhibitors was tested in the MMP assay with recombinant purified 
MMP-2 (rMMP-2), MMP-9 (rMMP-9) and CM from HT1080 cells. NNGH potently inhibited 
the MMP activity in all tested systems (Fig. 3.9). The activity of rMMPs was strongly inhibited 
by rTIMPs; however, rTIMPs did not affect the MMP activity in CM, even at concentrations 
10-times higher than required for the inhibition of the activity of recombinant MMP-2 and -9. 
As MMPs may be secreted in a complex with endogenous TIMPs [181], we speculated that 
this might prevent binding of exogenous rTIMPs and subsequent MMP activity inhibition. To 
prove this hypothesis, we down-regulated endogenous TIMP-1 or TIMP-2 in HT1080 cells 
with siRNA (Fig. 3.18) and determined MMP activity in their CM, in both the presence and 
absence of rTIMPs. However, the inhibition of MMP activity by rTIMPs in this CM could 
Figure 3.9. The MMP inhibitor NNGH 
but not recombnant TIMP-1 and 
TIMP-2 protens nhbt the MMP actvty 
in CM. NNGH, rTIMP-1 and rTIMP-2 
were added to CM at concentratons 
10 µM, 0.16 µM and 0.4 µM, respec-
tvely. The cell were transfected wth 
siTIMP-1 or siTIMP-2. siLuc was used 
as an rrelevant control sRNA. Data s 
shown as mean +/- SE, n=2, *P<0.05.
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not be observed. Moreover, rTIMP-2 partly lost its ability to inhibit activity of rMMPs after 
pre-incubation with CM of HT1080 cells (data not shown). This indicated that there might be 
a TIMP-scavenging/neutralising activity in cell culture media supernatant of HT1080 cells.
The addition of rTIMPs to HT1080 cells in the transwell assay did not affect cell invasion 
or migration significantly (data not shown), as it did not inhibit MMP activity in CM 
(Fig. 3.9). However, the treatment of cells with the small molecular MMP inhibitor NNGH, 
led to a reduction of cell invasion to 50-60 % of the control level (Fig. 3.10). This reduction of 
cell invasion occurred both in cells irradiated with 2 Gy and non-irradiated cells. This finding 
indicates that in our experimental system, cell invasion required MMP activity.
The combined treatment modality with patupilone and IR is more potent in 
vivo than in cellular model systems. Most probably this is due to the addi-
tional treatment effects on the level of the tumor microenvironment, which 
may be mediated by tumor cells [79, 157]. Herein, we investigated an effect 
of the indicated treatment regimens on one of the important components of 
the tumor microenvironment, namely MMPs. We identified that the activity of 
secreted MMPs was up-regulated after treatment with IR and that pre-treat-
ment with patupilone could diminish this increase (Fig. 3.4). MMP activity 
is required for tumor cell invasion as well as for other cellular processes. 
In this study, tumor cell invasive capacity was indeed increased after IR 
and, in line with the events on the level of MMP activity, patupilone could 
counteract this effect of IR (Fig. 3.8).
Figure 3.10. The MMP inhibitor NNGH inhibits the cell invasion. 
The cells were plated with 10 µM NNGH 4 h prior to irradiation. 
The rate of nvason was evaluated 24 h after platng. The results 
are plotted as percentage of the invading cells relative to control, 
mean +/- SE, n≥3, *P<0.05, **P<0.01, ***P<0.001.
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3.3 The mechanisms of inhibition of ionizing radiation-induced                        
      MMP activity by patupilone 
3.3.1 Patupilone does not prevent ionizing radiation-induced cell cycle arrest
Both ionizing radiation and microtubule stabilizing agents may alter the cell cycle distribution 
of the treated cells in a time-, dose- and cell line-dependent way. Ionizing radiation induces 
cell cycle arrest by activation of the G2-checkpoint in tumor cells with subsequent accumulation 
of cells in the G2 phase of the cell cycle [20]. Patupilone has various, dose-dependent effects 
on cell cycle distribution. A strong accumulation of cells in G2/M-phase occurs after treatment 
with high cytotoxic doses [153]. After treatment with lower doses both S phase accumulation 
[79] and G1 arrest [182] were observed. We hypothesized that the counter effect of patupilone 
on IR-induced MMP activity may be due to the influence on the cell cycle distribution, for 
example, the compound might prevent G2/M accumulation after irradiation. 
We assessed the cell cycle distribution of HT1080 and HCT116 cells after treatment with 
patupilone and IR by flow cytometry. No change in cell cycle distribution was observed in 
HT1080 cells after treatment with either 2 Gy or 0.2 nM of patupilone (Fig. 3.11). Irradiation 
with 10 Gy induced accumulation of cells in G2/M phase, which occurred within 12 h after 
treatment. Patupilone, even after treatment with a very high cytotoxic dose, namely 2 nM, 
only minimally affected cell cycle distribution, inducing only minor accumulation in S phase: 
39 % (treated) vs. 29 % (control) (Fig, 3.11A). After combined treatment with 10 Gy of IR 
and 0.2 nM patupilone cell cycle distribution was similar to the one after treatment with 
radiation alone (Fig. 3.11B, left). In HCT116 cells, similar results were observed. Treatment 
with 0.5 nM patupilone did not affect cell cycle distribution (Fig. 3.11B, right). Only after 
treatment with very high concentrations of patupilone, namely > 20 nM (2 nM is patupilone 
IC100 in HCT116 cells), could the classical G2/M phase arrest be detected. Treatment with 2 
nM patupilone led to accumulation of cells in S-phase. G2/M accumulation was observed 
after 5Gy IR alone and in combination with 0.5 nM patupilone (10-13 % of cells in G2/M 
phase after IR vs. 6 % of non-irradiated cells). 
Based on these observations we can conclude that the counteracting effect of patupilone 
on IR-induced MMP activity and cell invasion is not due to cell cycle-related mechanisms, 
as patupilone at the corresponding concentrations did not influence cell cycle distribution of 
non-irradiated HT1080 and HCT116 cells and did not prevent G2/M accumulation after IR.
3.3.2 Cell cycle-related changes of MMP activity in conditioned cell culture 
media
IR induced MMP activity in the CM and cell cycle arrest with an accumulation of cells in 
G2/M phase. We questioned if cell cycle arrest was a sufficient factor that could induce the 
MMP activity levels in response to IR. To approach this question, HT1080 cells were treated 
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with hydroxiurea (HU) and aphidicolin (Aph) – chemical compounds inducing S phase 
accumulation [43]. The accumulation of cells in the S phase of the cell cycle was confirmed 
by flow cytometry (data not shown) and MMP activity in CM of cells in S phase was 
determined. 
Treatment of cells with both compounds resulted in the induction of MMP activity in 
CM. The increase after incubation with 1mM HU was 3.7-fold, and 15-fold after 4 µg/mL 
Aph (Fig. 3.12). Measurements of MMP mRNA levels showed that MMPs were induced 
on the transcriptional level (data not shown). Thus, we showed that chemically-induced cell 
A
B
Figure 3.11. Cell cycle dstrbuton after the treatment wth patuplone and IR. The cell cycle dstrbuton was 
assessed after the ndcated treatments. Patuplone was admnstered 24 h pror to IR. The cell cycle dstrbuton 
was assessed in HT1080 12 and 24 h after IR; in HCT116 cells 24 h after IR.
Hystograms – the representative cell cycle distribution of HT1080 cells (A); bar diagrams – mean +/- SE, n=3 (B).
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cycle arrest in S phase can induce MMP activity in CM, as well as cell cycle arrest in G2/M 
phase after IR. To test whether the induction of MMP activity in CM after treatment with IR 
or HU/Aph occurs via similar mechanisms, we irradiated the cells which were arrested in 
the S phase and determined MMP activity in their CM. As shown in Fig. 3.12, no additive 
increase of MMP activity was observed after combined treatment with IR and hydroxyurea or 
aphidicolin. The result suggests that the induction of the MMP activity occurred via related 
mechanisms, both after irradiation and after S phase arrest. 
The results demonstrated that on the one hand the induction of MMP activity after IR is 
not due to G2/M phase accumulation but rather due to cell cycle arrest, as S phase arrest with 
hydroxyurea and aphidicolin also induced MM activity. On the other hand, these findings 
indicated once more that MMP activity induction might be a part of a cellular stress response, 
which can be induced by different means, e.g. IR, cell cycle arrest or treatment with cytotoxic 
compounds (see Chapter 3.2.3).        
3.3.3 Patupilone does not interfere with MMP expression on transcriptional 
level 
Previous reports claim that ionizing radiation induces MMPs on the level of transcription 
[100, 183]. As such, we investigated if patupilone can decrease IR-induced MMPs mRNA 
levels. qRT-PCR was performed with mRNA samples obtained form HT1080 cells treated 
with 0.2 nM patupilone and IR (2 and 10 Gy), alone and in combination. Transcription of 
MMP-2, -9 and -14 was induced by approximately 50% 24 h after irradiation with 10Gy 
(P>0.05, Fig. 3.13). Patupilone altered neither the basal level of MMP transcription nor the 
level of IR-enhanced transcription. We also assessed the mRNA levels of MMP-1 and MMP-3 
but did not observe any significant changes after any applied treatments (data not shown). In 
HCT116 cells, only mRNA levels of MMP-2 and MMP-9 were elevated by 1.8- and 1.5-fold, 
Figure 3.12. The cell cycle arrest nduces MMP actvty n 
the cell culture meda supernatant. The cells were treated 
with 1 mM hydroxyurea (HU) or 4 µg/mL aphidicolin (Aph) 
for 36 h and irradiated 18 h before the MMP activity analysis. 
Mean +/- SE, n≥2.
3.3 The mechanisms of inhibition of IR-induced MMP activity by patupilone 
49
respectively, after irradiation with 5Gy. Patupilone did not effect basal or IR-induced MMP 
transcription (data not shown).
To confirm that patupilone does not alter induced MMPs transcription, cells were treated 
with an established transcriptional inducer of MMPs, phorbol-12-myristate-13-acetate (PMA) 
in combination with patupilone. PMA activates PKC and the activation of its downstream 
pathways leads to increased transcription of MMP-1, -9, and -14 and TIMP-1 [125-126, 184]. 
In our experiment, 40 μg/mL PMA upregulated MMP-9 and MMP-1 transcription, 13-fold and 
6-fold, respectively. However, we could not detect up-regulation of MMP-14 (Fig. 3.14A). 
Pre-treatment with patupilone failed to inhibit PMA-induced transcription. Never-the-less, 
we again observed an inhibitory effect of patupilone on the PMA-induced MMP activity in 
CM of HT1080 cells (Fig. 3.14B). The proteolytic activity of MMPs doubled after incubation 
with PMA but was only induced by 1.6-fold when cells were pre-treated with 0.2 nM of 
patupilone (P=0.0001). Interestingly, the magnitude of PMA-induced MMP activity inhibition 
Figure 3.13. Patuplone does not 
alter MMP mRNA levels. The MMP 
mRNA levels in HT1080 cells were 
determned usng qRT-PCR 24 h 
after treatment wth IR. Patuplone 
was appled on cells 24 h pror to 
IR. Data is shown as mean +/- 
SE, n≥4, *P<0.05, **P<0.01.
Figure 3.14. Patupilone does not alter the PMA-induced MMP mRNA levels. HT1080 cells were treated with 
patupilone 24 h before application of 40 μg/mL PMA. 20 hours thereafter, mRNA for qRT-PCR (A) and CM for 
determination of the MMP activity (B) were isolated. Data is shown as mean +/- SE, n>4, *P<0.05, **P<0.01.
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by patupilone was similar to the inhibition observed for IR-induced activity (Fig. 3.4).
3.3.4 Patupilone has no effect on MMP intracellular and extracellular protein 
levels 
No effect of patupilone treatment on the level of MMP transcription was observed. MMP 
activity, however, is regulated on multiple levels, including proteolytic activation and secre-
tion (see Chapter 1.4.1). Furthermore, MTSAs were shown to inhibit MMP activity in the 
extracellular space by interfering with the MMP secretion process [48]. To probe whether 
the treatment with IR and patupilone influence expression or secretion of MMP proteins, we 
probed intracellular and extracellular protein levels of MMP-1, -2, -3, -9 and -14. MMP-2 
(gelatinase A) and MMP-9 (gelatinase B) are the most relevant MMPs for the first step of cell 
invasion – breaking the basal membrane. MMP-14 (MT1-MMP) is involved in proMMP-2 
activation [108]. MMP-1 (colagenase I) and MMP-3 (stromelysin I) are abundant in the CM 
of HT1080 cells as we demonstrated by MMP antibody array (Fig. 3.15).  
To determine the protein levels of the above-mentioned MMPs after treatment with 
patupilone and/or IR, we performed gelatine zymography with CM samples and Western 
blotting with CM and whole cell lysates of HT1080 cells. Gelatine zymography is a very 
sensitive SDS-PAGE-based technique which allows one to semi-quantitatively determine 
protein amount of zymogens and active forms of MMP-2 and MMP-9 by measuring their 
gelatinolytic activity [185]. Due to technical limitations (lack of antibody specificity and 
sensitivity), we could not detect MMP-1 and MMP-2 by western blotting; MMP-3 was 
Figure 3.15. MMP and TIMP proteins in CM of HT1080 cells. 
HT1080 cells were cultured for 24 h in serum free media. The 
CM was collected as descrbed n Materals and Methods and 
MMP antibody array was performed. pos – positive control.
detectable only in CM. As irradiation with 2 Gy only minimally affected MMP activity 
(Fig. 3.4) and mRNA level (Fig. 3.13) in HT1080 cells, we chose a radiation dose of 10 Gy 
for further studies. 
MMP-9 zymogen band could be detected by Western blotting in cell lysate at approximately 
100 kDa (predicted size 95-98 kDa) (Fig. 3.16). The MMP-9 band was detected in the CM 
of HT1080 cells on the level of ~80-90 kDa, which corresponds to the size of the active form 
of MMP-9 (predicted size 82 kDa). MMP-2 and MMP-3 were also present in CM as active 
forms; the MMP-2 band was detected at approximately 60-65 kDa (predicted size 62 kDa), 
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and the MMP-3 at 50 kDa (predicted size 45 kDa). We expected to observe both zymogen 
and an active form of MMP-14 in the whole cell lysate. However, only one strong band was 
detected at a size of approximately 60 kDa (predicted sizes are 66 kDa for MMP-14 zymogen 
and 57 kDa for active form), accompanied by multiple minor bands of various sizes, which 
were probably unspecific.
The treatment of cells with 10 Gy IR slightly induced the protein level of all tested 
MMPs in CM, as it was determined by western blotting and zymography assay (Fig. 3.16A, 
left). Patupilone treatment altered neither the basal protein level nor IR-induced protein level 
of MMP-2, -3 and -9 in CM. In whole cell lysates, we observed a slight increase in MMP-9 
protein levels after all of the applied treatments. However, the MMP-14 protein level did not 
change in whole cell lysate after any treatment applied. We also assessed amount of the MMP 
proteins after treatment with PMA and patupilone. As expected from the increased MMP-9 
transcription after PMA administration, the MMP-9 protein level was upregulated both in 
the cell lysate and in the CM, (Fig. 3.16, right). MMP-2 protein levels were not changed 
after indicated treatments, as can be seen on the zymography gel. Interestingly, in CM from 
PMA treated cells a double-band of MMP-2 active form can be observed, which probably 
represents truncated active forms of the proteinase. We also found a slightly up-regulated 
MMP-14 protein level, even though we did not observe an increase on the level of mRNA 
(Fig. 3.14A). The pre-treatment with patupilone neither altered the basal level of MMP nor 
reduced the protein levels that were up-regulated after PMA treatment.
These findings indicate that the inhibitory effect of patupilone on the IR-induced MMP 
activity was not due to down-regulation of MMP protein expression or secretion, as treatment 
with patupilone did not significantly affect extracellular and intracellular protein levels of 
MMPs in HT1080 cells.    
Figure 3.16. Proten level 
of MMPs s not affected by 
patuplone treatment. The 
MMP protein levels in HT1080 
cells were determned (A) n 
the CM by Western blot and 
by gelatne zymography and 
(B) in the whole cell lysates by 
Western blot. The cells were 
treated wth 0.2 nM patup-
lone 24 h before 10 Gy IR or 
application of 40 μg/ml PMA. 
20 hours thereafter, the cell 
lysates and the CM were col-
lected. N≥4.
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3.3.5 Patupilone down-regulates extracellular protein levels of TIMP-1 and 
TIMP-2
No significant changes of MMP mRNA or protein levels after treatment with patupilone were 
observed. Thus patupilone-dependent regulation of MMP activity is not due to the influence 
of the compound on MMP protein expression. Tissue inhibitors of MMPs (TIMPs) are 
important regulators of MMP activity. On the one hand, TIMPs are potent natural inhibitors 
of MMP enzymatic activity, on the other hand, TIMP-2 was shown to be a co-factor for extra-
cellular MMP-14-mediated activation of the MMP-2 zymogen (see Chapter 1.4.4). The coun-
teracting action of patupilone on the IR-dependent induction of MMP activity may be a result 
of patupilone interference with regulatory functions of TIMPs. Therefore, we investigated the 
effect of IR and patupilone on TIMP-1 and -2 transcription and protein expression.
On the level of transcription, we could only observe a minimal change of mRNA levels 
in response to irradiation. TIMP-1 and TIMP-2 mRNA levels increased less than 1.5-fold 
even after irradiation with 10 Gy (Fig. 3.17A). The basal and IR-induced TIMP mRNA levels 
were not affected by pre-treatment with patupilone. Treatment of cells with PMA induced the 
transcription of TIMP-1 (up to 2-fold, P=0.045) but not of TIMP-2 [186] (Fig. 3.17B). Again, 
patupilone did not influence PMA-regulated TIMP-1 transcription. 
The protein levels of TIMP-1 and TIMP-2 were assessed by Western blotting in CM 
and cell lysates after treatment with patupilone and IR or PMA. IR increased protein levels 
of both TIMP-1 and TIMP-2 in cell lysate and CM, compared to control cells (Fig. 3.18A, 
B, left). Protein levels of TIMP-1 and TIMP-2 in cell lysates after patupilone treatment 
were slightly elevated, when compared to control cells. We did not detect any changes in 
the basal level of TIMP proteins in CM after treatment with patupilone. The protein level of 
secreted TIMP-2 after treatment with IR in combination with patupilone was reduced, when 
compared to the protein level in CM after treatment with IR alone (P=0.02). For TIMP-1 the 
same trend could be observed but the difference was less pronounced. Contrary to the effect 
Figure 3.17. mRNA levels 
of TIMP-1 and TMP-2 are 
unaffected by patuplone 
treatment. HT1080 cells 
were treated wth patuplone 
24 h pror to rradaton (A) 
or application of 40 μg/mL 
PMA (B). 20 h thereafter, 
mRNA was solated for the 
qRT-PCR analyss. Data s 
shown as mean +/- SE, n≥4, 
*P<0.05, **P<0.01.
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observed in CM, TIMP protein levels in cell lysates after combined treatment with IR and 
patupilone were increased, when compared to IR treatment alone (Fig. 3.18B). The TIMP 
protein accumulation in cell lysate after patupilone treatment with concurrent reduction of the 
protein level in extracellular space indicates that TIMP protein secretion might be inhibited 
by patupilone.  
Exposure of the cells to PMA increased the amount of TIMP-1 protein both in the cell 
lysate and in CM. TIMP-2 protein levels were also up-regulated in the cell lysate, however, 
the level of TIMP-2 protein in CM was drastically reduced (Fig. 3.18A, B, right). Thus the 
accumulation of TIMP-2 protein in the cell lysate after incubation with PMA may result from 
reduced secretion. Pre-treatment with patupilone did not affect PMA-regulated TIMP-2 or 
TIMP-1 protein levels. 
These results demonstrate that treatment with patupilone does not affect TIMP-1 and 
Figure 3.18. IR-nduced proten 
levels of the secreted TIMP-1 and 
TIMP-2 are reduced after patup-
lone treatment. HT1080 cells were 
treated wth patuplone 24 h pror 
to rradaton or applcaton of 40 
μg/mL PMA. The protein levels 
of TIMPs n the CM (A) or n the 
cell lysates (B) was determined by 
Western blot 20 h thereafter. The 
representative blots are shown; 
quantification was made for at 
least 4 independent experiments, 
presented as mean +/- SE.
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TIMP-2 transcription (either basal or induced). However, the amount of TIMP proteins in 
CM is reduced after combined treatment with IR and patupilone, in comparison to radiation 
treatment alone.   
3.3.6 TIMP proteins are required for MMP activity induction after irradiation 
While IR increased TIMP protein levels, patupilone treatment reduced the IR-upregulated 
TIMP protein levels in the CM. Thus TIMP-1 and TIMP-2 may play a role in the mechanism 
of down-regulation of the IR-induced MMP activity by patupilone. To investigate whether 
TIMPs are involved in the aforementioned mechanism, we interfered with TIMP protein levels 
in one of two ways: by using a siRNA approach or with a TIMP protein function using TIMP-
neutralizing antibodies (nABs). 
MMP activity was assessed in the CM of cells treated with 10 Gy IR and/or 0.2 nM 
patupilone after down-regulation of TIMP-1 and TIMP-2 proteins using siRNA. The 
cellular response to treatment in control (siLuc)-transfected cells was the same as in non-
transfected cells. MMP activity in the CM was increased after treatment with IR, while pre-
treatment with patupilone significantly diminished the IR-induced MMP activity in the CM 
(relative increase was 1.9±0.13 and 1.6±0.14 after irradiation alone and combined treatment, 
respectively, P=0.0002, Fig. 3.20A). The transfection of cells with siTIMP-1 and siTIMP-2 
led to a down-regulation of TIMP protein levels which was maintained for the entire duration 
of the experiment (Fig. 3.19). In the CM derived from TIMP depleted cells, IR-dependent 
induction of MMP activity was weak and there was no longer any observable difference 
between MMP activity in the CM after treatment with IR alone and in combination with 
patupilone. In response to both treatments only a 1.5-fold increase in MMP activity could be 
Figure 3.19. Down-regulaton of TIMP proten levels by 
sRNA. The effectveness of proten down-regulaton n 
HT1080 cells was assessed by Western blot 96 h after 
transfecton wth sTIMP-1 or  sTIMP-2 n the cell lysate 
and in the cell culture media supernatant. siLuc was used 
as an rrelevant control sRNA.
determined (Fig. 3.20A), which was in the same range as the level of MMP activity in non-
transfected cells after combined treatment (Fig. 3.4). 
To confirm the result obtained with the siRNA-based approach, and in an attempt to 
assign the observed effect to the secreted TIMPs, we performed the experiment with cells that 
were exposed to neutralizing ABs against TIMP-1 or TIMP-2 during radiation and patupilone 
treatment. With control antibodies (goat IgG), as well as with the anti-TIMP-1 neutralizing 
ABs, the increase of MMP activity in CM was 2-fold after treatment with IR alone and 1.5-fold 
(P=0.0047) after combined treatment with IR and patupilone (Fig. 3.20B). These treatment-
dependent changes were also observed in the CM of cells without AB administration 
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(Fig. 3.4). However, treatment with anti-TIMP-2 neutralizing ABs resulted in an only 1.5-fold 
increase of MMP activity after IR (P=0.0073). Thus cell exposure to anti-TIMP-2 neutralizing 
ABs had the same effect on the treatment response on the level of MMP activity as depletion 
of TIMP-1 or -2 protein levels with the siRNA approach. This data suggests that TIMP-2, 
but not TIMP-1, is required for the up-regulation of MMP activity after IR treatment. This 
contradicted the results obtained in the experiment with siRNA directed against TIMP-1 and 
TIMP-2, which demonstrated the equal importance of both TIMPs. The contradiction could 
occur due to technical limitations. According to the manufacturer’s description, anti-TIMP-1 
neutralizing antibodies are less potent than anti-TIMP-2 neutralizing antibodies. Molar ratio 
TIMP:AB is recommended 1:3 and 1:5 for 50 % neutralization efficiency for anti-TIMP-2 
and anti-TIMP-1, respectively.   
Overall, the data indicates that the depletion of TIMP-1 or TIMP-2 prevents the activation 
of secreted MMPs after IR and suggests that patupilone counteracts IR-upregulated MMP 
activity through the regulation of TIMP-1 and -2 protein levels in CM.
3.3.7 Counteracting effect of patupilone to IR-dependent induction of MMP 
activity is due to interference with the MMP activation cascade 
TIMP-2 is a co-factor of the proMMP-2 activation in a well-described MMP-14 (MT1-MMP)-
dependent activation mechanism. The same role is proposed for TIMP-1 in proMMP-9 acti-
vation [120]. Our results demonstrated that patupilone reduced the amount of secreted TIMP 
proteins in CM after radiation (Fig. 3.18) and that TIMPs are required for the IR-dependent 
MMP activity upregulation, since after TIMP depletion with siRNA or neutralizing antibodies, 
the level of IR-increased MMP activity did not exceed the MMP activity level after combined 
Figure 3.20. Down-regu-
laton of the TIMP pro-
ten levels prevents the 
IR-medated MMP actvty 
nducton. The MMP actvty 
was determned n the CM 
of HT1080 cells after treat-
ment wth patuplone 24 h 
prior to IR. Mean +/- SE, 
n≥4, *P<0.05, **P<0.01, 
***P<0.001. (A) Anti-TIMP-1, 
ant-TIMP-2 or sotype con-
trol antbodes were appled 
on the cells at a concentra-
tion 0.7 μg/mL thrice: simultaneously with patupilone, 1 h before irradiation and with the serum-free media. 
(B) TIMP-1 or TIMP-2 was down-regulated using the siRNA approach. The cells were transfected with 200 
pmole of siTIMP-1 or 100 pmole of siTIMP-2 and siLuc.
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treatment (Fig. 3.20). Taken together, all this suggests that patupilone may interfere with the 
process of MMP activation after irradiation by depleting secreted TIMPs. To further test this 
hypothesis, we used the universal, unspecific activator of MMPs 4-amino-phenylmercuric 
acetate (APMA), which activates MMP zymogens by inducing conformational change inde-
pendently of natural regulation cascades (other MMPs and TIMPs) [187]. 
The CM samples of HT1080 cells, tested previously in the MMP activity assay (Fig. 3.4), 
were incubated with APMA (1 mM) for 1 h at 37 ºC and the MMP activity was measured 
once more. After activation with APMA, the measured MMP activity levels approximately 
doubled for all treatment conditions. In the APMA-activated samples, the MMP activity was 
1.7-fold higher in the CM of irradiated cells as compared to control cells. However, we could 
not observe the counteracting effect of patupilone on IR-induced MMP activity. The MMP 
activity levels in CM from cells treated with IR alone or in combination with patupilone 
were similar in APMA-activated CM (Fig. 3.21). This result confirmed that patupilone down-
regulated IR-induced MMP activity due to interference with proMMP activation processes, 
as the inhibitory effect of patupilone could no longer be observed when proMMPs in the CM 
were forced to an active state.
In an attempt to uncover mechanisms of the patupilone counteracting effect 
to the IR-dependent induction of MMP activity, we dissected the MMP regu-
lation cascade on different levels. Patupilone did not influence IR-induced 
events on the level of cell cycle distribution and transcription. Namely, it 
did not interfere with accumulation of cells in G2/M phase after IR (Fig. 
3.11B) and did not alter the IR-induced transcription of MMPs (Fig. 3.13) 
and TIMPs (Fig. 3.17A). Both MMP and TIMP protein levels were elevated 
in cell lysate and CM after treatment with 10 Gy of IR. Patupilone did not 
influence intracellular and extracellular MMPs protein levels (Fig. 3.16). 
Figure 3.21. Patuplone counteracts the IR-nduced MMP 
actvty by an nterference wth the MMP actvaton. The MMP 
activity was determined in The CM of HT1080 cells treated as 
on Fig. 3.4 with the indicated doses of patupilone and IR. The 
CM was ncubated wth 1 mM of APMA for 1 h at 37 °C for MMP 
activation or control buffer. Mean +/- SE, n=4, **P<0.01.
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However, the amount of extracellular TIMP-1 and TIMP-2 proteins after 
combined treatment with patupilone and IR was lower than after treatment 
with IR alone (Fig. 3.18A). Furthermore, the counteracting effect of 
patupilone on IR-induced MMP activity was not observed in CM of TIMP-1 
and TIMP-2 depleted cells (Fig. 3.20). After TIMP depletion, the level 
of IR-increased MMP activity did not exceed the MMP activity level after 
combined treatment, indicating that the proMMP activation processes 
after treatment with IR requires TIMPs. These results strongly suggest that 
patupilone counteracted IR-induced MMP activity due to interference with 
the MMP activation processes by depleting the levels of secreted TIMP-1 
and TIMP-2. This proposition was further confirmed by the finding that the 
inhibitory effect of patupilone on the IR-induced MMP activity could not 
be observed in CM after ex vivo activation of pro-MMPs (with APMA, Fig. 
3.21).
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4 Discussion
4.1 Radiosensitizing properties of patupilone
Microtubule stabilizing agents (MTSAs) have been tested in combination with ionizing 
radiation (IR) on the preclinical level in the in vitro and in vivo setting, revealing radioen-
hancement ranging from the additive to the supra-additive dimension. In the present work 
we confirmed the radiosensitizing effect of patupilone in a wide range of human cancer cells 
(colon carcinoma, fibrosarcoma, glioma and medulloblastoma). Patupilone already revealed 
its radiosensitizing capacity at very low concentrations, which were not cytotoxic, when 
applied alone and did not alter the microtubular (MT) structure of the cells. No alterations in 
cell cycle distribution were observed after treatment with these effective patupilone doses. 
One of the possible mechanisms of action at such a low concentrations may be reduction of 
MT dynamics with consequent aberrant mitosis and loss of replicative potential (clonogenic-
ity) of the tumor cells [77-78]. There are also indications that DNA repair might be influenced 
by MTSAs. The tumor suppressor p53 is found to localize with cellular microtubules and 
treatment with MT-stabilizer paclitaxel and destabilizer vincristine reduced the nuclear 
accumulation of p53 and the expression of mdm2 and p21 in response to DNA-damage [188]. 
When A549 cells were treated with low concentrations of MT-interfering drugs (which did 
not induce either mitotic arrest or change in tubulin polymerization rate) prior to doxorubicine 
exposure, nuclear accumulation of p53 was enhanced. This resulted in apoptotic cell death 
and sensitisation to doxorubicine [189].
MTSAs as chemotherapeutics have been in clinical use already for some decades [55-
58] but the step towards bringing combined treatment with MTSAs and IR into clinics is still 
in its initial phase. Phase I and II clinical trials demonstrated that combined treatment with 
paclitaxel and IR is well tolerated by patients with a broad range of cancers [190-194]. A 
recent Phase I study showed that patupilone can be safely combined with RT for malignancies 
of the central nervous system [195]. Even though the radioenhancing properties of MTSAs 
are widely accepted by the research and clinical community, surprisingly little is known about 
the mechanisms of their radiosensitizing effect. Our recent studies with patupilone challenged 
the long-standing dogma of the M phase arrest-related mechanism of radiosensitization ([77, 
79]. Our data also confirmed the accumulation of cells in the S phase after patupilone treat-
ment in human colon carcinoma and fibrosarcoma cells, which was previously reported in 
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MDR-overexpressing colon carcinoma cells [79]. Further research is still required to 
determine whether or not S phase accumulation is involved in a radiosensitizing effect, and 
if so, how this occurs.
The previous research work of our colleagues indicated a tumor microenvironment-oriented 
mode of action of the combined treatment with patupilone and IR [79, 157]. In the present 
study, we elucidated the effect of patupilone on IR-induced processes in the cancer cell 
microenvironment, with a focus on the MMP function.
4.2 Effect of combined treatment with patupilone and IR on MMP    
          function
MMPs play an important role in cancer progression by remodelling the extracellular matrix 
and regulating multiple biologically active molecules (reviewed in [132, 139, 179]. Based 
on their substrate profile, both the “cancer-promoting” and “cancer-inhibiting” functions of 
MMPs were proposed. However, overall, the sum of MMP actions promotes cancer progression 
(see Chapter 1.4.5). This assumption is supported by a great body of data showing that MMPs 
are overexpressed in multiple tumor types and correlate with aggressiveness of the disease 
(reviewed in [139]). Radiation treatment up-regulated MMPs in pre-clinical studies [32-33] 
and in patients with lung and breast cancer after radiotherapy [172]. MMPs are secreted both 
from tumor cells and cancer stromal cells. Studies of Bley and co-workers [157] and Escuin 
and co-workers [166] demonstrated that tumor cells mediate the influence of MTSAs on the 
tumor microenvironment. Thus, treatment with MTSAs did not result in disruption of tumor 
vasculature or changes in hypoxia levels or HIF-1 transcriptome in tumors, which originated 
from drug-resistant tumor cell lines, in contrast to their drug-sensitive counterpart tumors. 
These findings indicate that close investigation of tumor cell-secreted factors upon treatment 
with MTSA and IR may cast light on mechanisms of radioenhancement.
The vast majority of the known functions of MMPs are related to their enzymatic activity 
[139]. As such, we investigated the effect of clinically relevant treatment modalities, namely 
ionizing radiation and the chemotherapeutic agent patupilone, on the activity of MMPs. In 
particular, we investigated the activity of MMPs that are secreted from human cancer cells in 
response to the indicated treatment. Our main experimental system was the HT1080 human 
fibrosarcoma cell line which is a very well established model for investigation of MMP function 
and cell invasion [178, 196-198]. Another cell line that was used for the experiments was 
U251 cells, which originate from a human glioma, highly invasive and treatment-resistant 
tumor type [199-201]. 
We demonstrated that patupilone at low concentrations significantly decreased the IR-
induced MMP activity in conditioned cell culture media (CM) of these two different cancer 
cell lines. Patupilone also reduced the basal level of MMP activity in CM. At these effective 
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concentrations, patupilone had a minimal cytotoxic effect but exhibited radiosensitizing proper-
ties in the cell survival clonogenic assay. There is evidence that not only secreted MMPs but 
also MMPs at the cell surface, so-called MT-MMPs, are highly relevant to cell invasion, as 
they can activate proMMPs and, additionally, degrade components of the ECM by themselves 
[202-204]. Therefore, we checked whether the cell membrane-associated MMP activity was 
influenced by treatment with IR and/or patupilone but we did not observe any significant 
influence. This indicated that in our system the major effect of treatment with IR and patupi-
lone was on the secreted MMP activity. 
In the present work, we assessed MMP activity in CM using a FRET substrate-based 
assay that allows to determine the MMP activity in the native supernatant [205-206] without 
any specific pre-processing. The only drawback of the assay is that it is not possible to selec-
tively determine the enzymatic activities of individual MMPs. Selective substrate peptides 
and inhibitors for individual MMPs are not yet available because of the great similarity of 
the catalytic centres of the MMP family members [94]. Studies in the MMP field very often 
imply gelatin zymography [33, 100, 102] for the selective determination of MMP activity in 
body fluids or cell culture media. However, this technique actually measures an amount of 
MMP proteins, both active forms and zymogens, without considering the complex formation 
of MMPs with other regulatory molecules. This is a result of a technical limitation: complexes 
are denaturated during separation in an SDS polyacrylamide gel. In addition, MMP zymogens 
are non-proteolytically activated by conformational changes in the presence of SDS [185, 
207]. Thus the results of zymography assay rather reflect the MMP protein expression levels 
than the MMP activity in vivo. A direct correlation of MMP expression to function is not 
possible because of complex MMP activation and regulation processes [108]. The secreted 
MMP zymogens are activated in the extracellular space by mechanisms that have yet to be 
fully identified. The activated proteins may form complexes with TIMPs, which leads to the 
inhibition of enzymatic activity. Due to this complex regulatory cascade, only a certain fraction 
of expressed MMPs exhibit proteolytic activity in the extracellular space and the size of this 
fraction is difficult to predict. We believe that direct determination of MMP activity in condi-
tioned media – in contrast to assessment of the MMP expression – is the most relevant 
experimental endpoint, as MMP activity translates directly in most of MMP biological func-
tions [132]. For this purpose, the substrate cleavage assays (such as the FRET substrate-based 
assay described above) that allow to determine  the MMP enzymatic activity directly in 
biological samples are more accurate than the zymography assay.
To confirm that the increase of MMP activity after IR and patupilone down-regulation 
thereof is relevant to the functional cellular level, we assessed cell invasion after the 
respective treatments in a transwell chamber assay. This model system mimics the first step 
of metastasis: invasion of the tumor cell through the basal membrane. The cell invasion does 
not reflect the complexity of all MMP functions, as the MMP substrate repertoire is much 
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wider than the MMP-substrate components of the ECM. However, the transmigration assay 
is highly specific for MMP function as MMPs are required for the ECM degradation and 
successful transmigration [180]. The results of the cell invasion experiments with the human 
fibrosarcoma and glioma cells in the present study were well correlated with the results of the 
MMP activity experiments. The cell invasion of both human fibrosarcoma and glioma cells 
in the basement membrane mimicking system (MatrigelTM) was increased after irradiation. 
Pre-treatment of cells with patupilone abrogated this IR-induced increase of cell invasiveness. 
Treatment with patupilone alone decreased the basal level of cell invasiveness (in fibrosar-
coma cells). Cell invasion requires two functional components: cell motility and the degrada-
tion of extracellular matrix. Patupilone at low concentrations did not affect cell motility. Thus, 
the inhibitory effect of patupilone on cell invasion has to be attributed solely to a decrease of 
ECM-degrading capacity after treatment. The increase of cell invasion after IR was observed 
only at a low dose (up to 2 Gy). Higher doses of radiation led to the opposite effect – cell 
invasion was inhibited. This differential effect of IR on cell invasion is most likely related to 
IR-induced cytotoxicity. Cell invasion and motility in our experiments were decreased with 
IR dose escalation in correlation with IR-induced cytotoxicity (especially in glioma cells). 
Other reports previously demonstrated that only sub-lethal doses of IR induce cell invasion, 
which is inhibited by increasing cytotoxic IR doses [35, 208]. This phenomenon can explain 
the controversy in the literature on this topic. Both induction and suppression of cell invasion 
after IR were reported and it is difficult to draw a conclusion as the effect on cell survival at 
the corresponding doses of IR was not always described [28-31, 34]. The induction of cell 
invasion by sub-lethal radiation doses is a particularly important phenomenon in context of 
fractionated radiation treatment as the tumor dissemination rate may increase between the 
fractions.
The increase of cell invasion after IR can be attributed to enhanced MMP activity as a 
specific MMP inhibitor NNGH could inhibit cell invasion, both of untreated and irradiated 
cells. Interestingly, in our experiments we did not observe any inhibition of invasion by 
recombinant TIMP proteins (rTIMP), as shown in other experimental systems [209-210]. In 
our experiments, rTIMP-1 and -2 also could not inhibit MMP activity in conditioned media. 
TIMPs have very high affinity to MMPs and rapidly form complexes with the proteases. 
Furthermore, the complex formation does not always lead to inhibition of the MMP enzymatic 
activity but can also serve proMMP activation [108, 120, 131, 211]. There is evidence that 
TIMP-proMMP complexes may be formed inside the cell before secretion. Roderfeld and 
coworkers [181] demonstrated that proMMP-9-TIMP-1 complex is already present in the 
Golgi apparatus. We assumed that the pre-formed MMP complexes with endogenous TIMPs 
might prevent rTIMPs from inhibiting MMP activity in our experiment. Therefore, we used 
conditioned media of cells that had TIMPs down-regulated by siRNA approach; however, we 
still did not see any inhibitory effect of rTIMPs on MMP activity. Furthermore, incubation of 
4 Discussion
62
exogenous TIMPs with conditioned cell culture media of HT1080 cells reduced their ability 
for inhibition of recombinant MMPs. There are no known natural inhibitors of TIMPs, even 
if MMPs can be considered so [120]. However, our data suggests that there is indeed an un-
known TIMP-scavenging activity in conditioned media of human fibrosarcoma cells.
IR regulates MMP expression on the transcriptional level [28, 170, 183]. Promoter 
regions of MMPs contain binding sites for transcriptional factors, which are induced after 
activation of stress signalling pathways (e.g. MAPK and Nf-kB) [73-74, 96, 212]. This makes 
MMPs a part of a cellular stress response. Our results strongly supports this assumption. The 
treatment of cells with hydroxyurea or aphidicolin and the subsequent S phase arrest led to an 
elevation of MMP activity in CM and up-regulation of MMP expression on a transcriptional 
level. We also observed a strong increase of MMP activity in CM after treatment with high 
cytotoxic doses of microtubule-interfering agents (patupilone, nocodazole, vincristine) and 
doxorubicine (data not shown). The mechanism of MMP activation after the above-
mentioned stimuli is also most probably related to the activation of the stress response path-
ways.  Doxorubicine was shown to activate MMP-9 expression via p38MAPK and MMP-2 
expression via ERK and JUNK signalling cascades [212]. Paclitaxel induced the Nf-kB 
pathway in breast and ovarian cancer cells [73-74]; patupilone also induced apoptosis in 
colon carcinoma cells via activation of Nf-kB pathway [75]. Since MMPs can activate growth 
and survival factors [115] and may be involved in the protection of cells from apoptosis [116], 
they indeed can be an important component of stress response.
Data on the transcriptional effects of patupilone and paclitaxel is rather poor. Treatment 
with high cytotoxic concentrations of the compounds leads to the activation of the aforemen-
tioned stress response pathways [73, 213] and to the induction of cell cycle checkpoint-related 
genes. This is most likely a result of MT stabilization and MTSA-induced M phase arrest [71]. 
No alterations in the gene expression were reported for low concentrations of MTSAs and we 
also could not observe any effect of patupilone at a  low concentration on gene expression of 
MMPs and TIMPs.
MMP activity may be regulated by MTSAs on the level of MMP protein secretion. The 
intracellular transport of MMPs and TIMPs depends at least in part on an intact MT system 
[113-114, 174]. Paclitaxel treatment impaired the secretion of MMP-2 and -9 and significantly 
reduced invasive activity of melanoma cells [48]. In our attempt to elucidate the mechanism of 
the counteracting effect of patupilone on IR-induced MMP activity, we excluded cell cycle-
related and transcriptional mechanisms, as patupilone did not interfere with IR-induced 
G2 arrest and IR-induced MMP transcription. Our assumption that patupilone mediates its 
counteracting effect on IR-induced MMP activity via microtubule- and secretion-related 
mechanisms is supported by the following findings: IR-induced MMP activity was also down-
regulated after treatment with other microtubule-interfering agents, such as paclitaxel and no-
codazole. Furthermore, we observed an accumulation of TIMP proteins inside the cells and a 
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reduced amount of TIMP protein levels in the CM after combined treatment, when compared 
to radiation treatment alone. However, the intra- and extracellular levels of MMP proteins did 
not change after treatment with patupilone. This indicated that the secretion of TIMPs, but not 
MMPs, could be inhibited by MTSA. Various mechanisms of intracellular transport of different 
MMPs and TIMPs were described previously. Sbai et al [114] demonstrated that, in mouse 
neuronal cells, the co-localization of overexpressed MMP-2, MMP-9 and TIMP-1 proteins 
with MT-dependent molecular motor kinesin differs substantially. TIMP-1 was associated 
with kinesin to a lower extent than MMP-2 and MMP-9. This study does not directly explain 
our findings. However, it strongly indicates that secretory mechanisms may play a role in the 
specific regulation of individual MMPs and TIMPs levels and activity, and that we can only 
start to understand these processes at the molecular level.
We demonstrated that IR-induced TIMP-1 and TIMP-2 extracellular protein levels were 
diminished by patupilone. This finding indicated that TIMPs might play a role in the inhibitory 
effect of patupilone on IR-induced MMP activity. Indeed, in the present study, IR failed to 
enhance MMP activity to the full extent if cellular and secreted TIMP-1 or TIMP-2 protein 
levels were down-regulated. After TIMP depletion, the level of IR-increased MMP activity 
did not exceed the level of MMP activity after combined treatment, indicating that a) the 
proMMP activation processes after irradiation require TIMPs, and b) patupilone interferes 
with the activation process by regulating extracellular TIMP levels. Additionally, the activation of 
MMPs in CM with 4-aminophenylmercuric acetate (APMA) leads to similar levels of MMP 
activity in CM, when collected after treatment with IR (both alone and in combination with 
patupilone). APMA activates MMPs potently and non-specifically by chelating cystein in the 
pro-enzyme domain. This leads to conformational change, which rescues the catalytic center. 
Therefore, an increase of MMP activity after incubation with APMA is due to the activation 
of MMP zymogens, which are present in CM, while the activity of MMPs that are trapped 
in inhibitory complexes with TIMPs remains concealed [106]. The equal activity in APMA-
treated CM of cells after radiation and combined treatment also reflects the equal MMP pro-
tein levels after these treatments.
Taken collectively, our results suggest that the counteracting effect of patupilone on 
IR-induced MMP activity can be attributed to a reduction of MMP zymogen activation pro-
cesses after patupilone treatment due to depletion of secreted TIMPs (see Outlook, chapter 
5.1), which play a role in proMMP activation. In our study, we showed that both TIMP-2 and 
TIMP-1 are important for the induction of MMP activity after radiation treatment. This is an 
important finding, since the role of TIMP-2 in activation of proMMP-2 is well known, but 
the role of TIMP-1 in proMMP-9 activation has only been predicted based on the structural 
similarities of their complexes [120]. It is widely appreciated that the ratio of TIMPs and 
MMPs is a very important factor in the regulation of MMP activity. According to the current 
model of proMMP-2 activation by MT1-MMP [108], TIMP-2 is forming a complex with 
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proMMP-2 and serves as an adaptor for binding to MT1-MMP. A certain level of TIMPs is 
required for optimal activation [131] and both reduction and increase of TIMP-2/proMMP-2 
ratio leads to inhibition of proMMP activation either due to a lack of “adaptor” TIMP-2 or as 
a result of a competition between “empty” TIMP-2 and TIMP-2/proMMP-2 complexes for 
MT1-MMP binding site [108, 211]. In addition, TIMP-2 can inhibit proteolytic activity of 
the activated MMP-2. The present work confirmed that the TIMP/MMP ratio is important for 
proMMP activation. More importantly, we demonstrate that patupilone disturbs this ratio and 
thereby interferes with MMP activation after IR.
4.3 Translational significance
To the best of our knowledge, we have demonstrated, for the first time, that patupilone 
can counteract IR-induced activity of secreted MMPs and subsequent increase of cell inva-
sion. Of particular interest is that the counteracting effect of patupilone can be observed in 
human glioma cells. Glioblastoma (or grade IV glioma) is one of the most treatment-resistant 
primary tumors in adults. Despite of recent introduction of the new chemotherapeutic agent 
temozolomide to the standard therapy of glioblastoma, median overall survival still remains 
at a rate of 14 months. Thus, the challenge remains to improve the treatment outcome [200]. 
The main established reasons associated with poor prognosis are extensive infiltration of sur-
rounding brain tissue by tumor cells and the blood-brain barrier as an obstacle for the adequate 
delivery of cytotoxic agents [214]. Radiation therapy is a standard treatment for gliomas in 
spite of evidence that irradiation can promote glioma cell migration and invasiveness in vitro 
and in vivo, which can be mediated by up-regulation of MMPs [201, 208, 215]. Patupilone 
was already shown to decrease the occurrence of lymph node metastasis in mouse orthotopic 
prostate tumor model. [91]. The ability of patupilone to cross a blood-brain barrier and to 
retain in brain tissues [216-217] makes patupilone a very potent and promising chemothera-
peutical agent for brain malignancies. The capacity of patupilone to inhibit IR-induced glioma 
cell invasion, shown in the present study, increases the value of the compound as candidate 
for a combined treatment modality with radiation therapy for glioblastoma treatment.
MMPs were, for a long time, considered to be pro-malignant factors on the basis of their 
massive upregulation in malignant tissues. The pharmacological industry puts a substantial 
effort into the development of MMP-inhibitors (MMPIs) as anti-cancer agents. MMPIs were 
exhibiting good efficacy in pre-clinical studies. For example, batimastat (a broad-spectrum 
MMP inhibitor) reduced metastasis and inhibited local re-growth of tumors in nude mice 
after resection of human breast cancer xenografts [218]. MMPIs for cancer treatment reached 
Phase III clinical trials but so far all of them failed to show any clinical benefit for cancer 
patients and exhibited severe side effects including musculoskeletal pain and inflammation 
[219-221]. One of the possible reasons for such an unsuccessful entry in the clinic was the 
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unspecific nature of these inhibitors. Regulation, structure and substrates of MMPs overlap 
to a great extent. Therefore, research on this group of proteins is not a trivial task and there 
are no inhibitors that are selective to certain MMP family members. Broad-spectrum inhibi-
tion was ineffective in patients; however, highly selective and specific inhibition of MMPs 
could still be an effective treatment for cancer, if care is taken to target only relevant MMPs 
in specific disease settings.
Clinical trials with MMPIs also met difficulties in interpretation. There is a discrepancy 
between the design of pre-clinical and clinical studies. While in the animal model studies, 
MMPIs were administered at early disease stage and maintained throughout disease progression 
with tumor growth control as an experimental endpoint, human clinical trials focused on 
administration of inhibitors only at end stage disease. Thus, the best window for MMPI treat-
ment may have been missed [220, 222]. Furthermore, MMPIs do not have antiproliferative 
properties and are therefore not expected to result in responses assessed by classical clinical 
endpoints for cytotoxic agents. Instead, stable disease must be accepted as the best response, 
at least in case of MMPIs, as a single treatment modality [219].
An additional possible reason for the failure of MMPIs is the protective role of MMPs 
in tumor progression that has been recognized only during the last decade. Most of the data 
derives from genetic studies in murine models of tumor progression where ablation of specific 
MMPs actually resulted in accelerated disease progression. For example, squamous cell 
carcinomas that developed in MMP-3-knock-out animals had a faster initial rate of growth 
and tumor progression as compared to their wild-type controls [223]. HPV16-driven carcinomas 
that arose in MMP-9 deficient mice were more aggressive and of higher grade, compared to 
tumors found growing in wild-type animals. The authors determined that the MMP-9 effect 
derived from stromal inflammatory cells [224]. MMP-9 activity is also important for the 
generation of angiostatin and tumstatin (anti-angiogenic factors), as was shown in a study 
where large angiogenic tumors occurred in MMP-9-knock-out mice [225]. Finally, all MMPIs 
tested to date were directed against the proteolytic activity of MMPs. However, MMPs 
also reveal non-proteolytic functions that are mediated via their hemopexin domain. The 
hemopexin domain of proMMP-9, but not its proteolytic activity, was necessary for MMP-9-me-
diated epithelial cell migration in a transwell chamber assay [226]. The cytoplasmic tail of MMP-
14 carries a migration-promoting function on macrophages [227]. In chronic lymphocytic 
leukemia, MMP-9 promotes B cell survival in a non-proteolytic fashion via its hemopexin 
domain by induction of the intracellular signalling, which prevents B cell apoptosis [228]. 
The nonproteolytic functions of MMPs could also explain why previous clinical trials using 
inhibitors of the MMP catalytic domains failed as anticancer therapeutics. In spite of all 
complications, MMPs are a very attractive target and many clinical trials are ongoing with 
new generation of more selective MMPI compounds [220].
The natural MMP inhibitors TIMPs could also be used for anti-cancer therapy as they 
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exhibited anti-cancer activity. Ectopic expression of human TIMP-1 in mice inhibited growth 
of Ehrlich tumor allografts by suppression of neovascularization [229] and brain metastasis 
of fibrosarcoma xenografts [230]. After being injected into the mammary fat pads of nude 
mice, TIMP-2 producing tumor breast cells grew slower as xenografts and showed a dramatic 
decrease in size and number of lung metastatic tumors [231-232]. The adenoviral expression 
of TIMP-3 in human melanoma xenografts promoted apoptosis in melanoma cells through 
stabilization of a number of death receptors and activation of their apoptotic signaling cascade 
through caspase-8 [233]. It was also reported that TIMP-3 deficiency in the host stroma, but 
not in tumor xenograft, leads to enhanced tumor growth and angiogenesis. Thus, TIMP-3 
located within the tumor microenvironment can inhibit tumorigenesis [234]. 
However, TIMPs can not only inhibit, but also promote, tumor progression through 
various mechanisms. The expression of TIMP-1 enhanced the tumorigenicity in K14-
HPV16 transgenic mice by potentiating keratinocyte hyperproliferation and the appearance 
of chromosomal aberrations in premalignant cells [235]. TIMP-1 also protected MCF-7 breast 
cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1 [236]. 
A highly invasive subclone of U87 cells exhibited two-fold elevation of TIMP-2 and over-
expression TIMP-2 in parental U87 cells promoted MMP-2 activation and invasion in these 
glioblastoma cells [237]. TIMPs can activate pro-survival cellular signaling pathways as re-
ported for TIMP-2, which displays growth stimulatory activity mediated by the activation of 
Nf-kB in A549 lung epithelial cells [238] and for TIMP-1, which enhanced cell growth by 
inhibition of metalloproteinases and activation of ERK1/2 and p38 [239]. TIMP-1 also plays 
various roles during tumor development. Early subcutaneous growth and angiogenesis of en-
grafted B16 melanoma was promoted in mice by overexpressing human TIMP-1 in the liver; 
however, the lung colonizing ability of the melanoma cells later during tumor development 
dramatically decreased [240]. Since TIMPs display paradoxical effects on cell proliferation 
and cell death, it is difficult to generalize their effect on tumor growth and predict the out-
come of TIMP interference. The present study demonstrated that the induction of TIMP-1 and 
TIMP-2 after IR can lead to increased MMP activation and subsequent cell invasion.
Therapeutic agents that cleverly target members of MMP and TIMP families in selective 
and disease/function-specific ways can represent an interesting class of agents for a combina-
tion with ionizing radiation. They can join a group of potential radioenhancing compounds 
together with DNA repair-interfering agents, signal transduction pathway inhibitors and MTSAs. 
This study demonstrated that the MTSA patupilone is a compound of great interest. It is a 
potent inhibitor of tumor cell proliferation under hypoxic and normoxic conditions, a very 
promising anti-metastatic and anti-angiogenic agent, an inducer of apoptosis, and a potent 
radiosensitizer in vivo and in vitro as described elsewhere [60, 75, 79, 88, 91-93, 157, 167]. 
In addition and as demonstrated in the present work, patupilone inhibits IR-induced activity 
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of secreted MMPs and IR-induced cell invasiveness. Since IR-induced MMP activity may 
be relevant beyond tumor cell dissemination, due to the complex MMP functions in cancer 
progression, the combined treatment modality of IR and patupilone might indeed be of a great 
clinical benefit for cancer treatment.
68
5 Outlook
5.1 Microtubule dependent secretion of TIMPs protein 
The present study demonstrated that patupilone diminishes the IR-induced increase of extra-
cellular MMP activity. This effect of patupilone was observed at a very low dose of the MTSA 
(e.g. 0.2 nM in HT1080 human fibrosarcoma cell line). This dose was not cytotoxic when 
applied alone and did not alter the morphology of the microtubular cytoskeleton. However, 
patupilone at this dose enhanced IR-induced cytotoxicity, exhibiting a radiosensitizing effect. 
Our findings strongly suggest that the counteracting effect of patupilone on IR-induced MMP 
activity is attributed to interference with the MMP activation processes due to a depletion of 
secreted TIMP-1 and TIMP-2 proteins. We demonstrated that after treatment with patupilone, 
in combination with IR, the amount of secreted TIMPs in conditioned cell culture media of 
irradiated cells was reduced, when compared to the level of secreted TIMPs after IR treatment 
alone. We simultaneously observed a trend towards the accumulation of the TIMP proteins in 
cell lysates. These results indicated that patupilone might interfere with secretion of TIMP-1 
and TIMP-2 after radiation treatment. Furthermore, our data suggested that the inhibitory 
effect of patupilone is linked to the microtubular system, as other MT-interfering agents 
(paclitaxel and nocodazole) exhibited similar properties and also inhibited IR-induced extra-
cellular MMP activity.
TIMP-1 protein is transported in vesicles, which co-localize with microtubule structures 
and associated with the MT-dependent molecular motor kinesin, as reported in mouse neuronal 
cells [114]. MMP-2 and MMP-9 also co-localize with MTs in mouse neuronal cells and in 
human melanoma cells. Furthermore, secretion of MMPs can be inhibited by the microtubule-
stabilizing agent paclitaxel [48, 174].  To our knowledge, we demonstrated for the first time 
that TIMP secretion may be inhibited by the MTSA patupilone. To confirm this hypothesis, 
confocal microscopy techniques could be employed. We are currently generating plasmid 
vectors for expression of fluorescent protein-labelled TIMPs. Figure 5.1 demonstrates an 
HT1080 cell, which transiently expresses TIMP-1-EGFP:  a vesicular subcellular localization 
of TIMP-1-EGFP can be observed. We intend to generate TIMP-1 and TIMP-2-EGFP expressing 
cells. These cells will be treated with IR, alone and in combination with patupilone, and the 
rate of vesicular trafficking will be assessed by Fluorescence Recovery after Photobleaching 
(FRAP) technique. FRAP allows to measure the fluorescent recovery of a bleached area of 
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the cytoplasm [241]. We expect a slower fluorescence recovery of a bleached region in cells 
treated with patupilone, which could indicate impaired MT-dependent vesicular trafficking of 
fluorescent TIMPs. The drawback of the FRAP approach, however, is that with this technique 
it is not possible to differentiate between MT-dependent and independent (e.g. cytoplasmic 
diffusion) vesicular trafficking. To overcome this limitation and to attribute the observed 
phenomenon to MT-dependent processes, further microscopic observations can be performed. 
The fluorescent TIMP-overexpressing cells may be stained with life cell fluorescent MT dye 
(Cellular LightsTM, Invitrogen) and the tracking of fluorescent vesicles along the MTs may be 
performed. Again the rate of movement of TIMP-GFP-labelled vesicles (travelling speed or 
distance) is expected to be lower in cells treated with patupilone and IR than in those treated 
with IR alone.
5.2 Clinical aspects of the MMP activity alterations after treatment       
      with patupilone and IR
The present study once again confirmed that IR increases MMP activity and tumor cell 
invasiveness in a preclinical setting [28-31, 208]. Clinical insights in this area are very 
limited. We found only two reports in the literature concerning the upregulation of MMP 
activity in plasma and rectal mucosa of cancer patients after radiotherapy [172, 242].  More 
intense translational and clinical studies are required to adequately evaluate the role of radio-
therapy in the potentially disadvantageous activation of MMPs in irradiated tissues. MMP 
activity after radiotherapy may be determined not only in tissues obtained by biopsy (invasive 
method) but also in body liquids, like plasma or urine [33]. Furthermore more intense sys-
temic studies are required to estimate of the role of radiotherapy in tumor dissemination.
We demonstrated herein that patupilone can diminish IR-induced extracellular MMP 
activity. The biological relevance of this finding can be demonstrated in established human 
tumor cells, as patupilone also inhibited IR-induced cell invasiveness in vitro. The next step 
must be a demonstration of the clinical relevance of our findings. Possible experimental 
5 Outlook
Figure 5.1. Expression of TIMP-1-EGFP in the HT1080 
cells. The cells were transently transfected wth the 
pEGFP-TIMP-1 vector. Arrows indicate the vesicular sub-
cellular localization of TIMP-1-EGFP (green), scale 
bar 5 μm.
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end-points could be: (i) determination of MMP activity in vivo in tissues after combined 
treatment, (ii) an assessment of tumor invasiveness and tumor cell dissemination in vivo (his-
tological characterization of invasive tumor margins or frequency of distant metastasis) and 
(iii) histological evaluation of tissue TIMP and/or MMP protein expression after combined 
treatment with patupilone and IR. As the administration of MTSAs with IR is not a standard 
treatment modality today, no patient biopsies are available for histological analysis of these 
endpoints. Currently, the use of animal orthotopic tumor models is the best available ap-
proach for addressing these questions.
One of the clinically relevant findings of the present work is that patupilone can inhibit 
IR-induced invasion of human glioma cells in vitro. Gliomas are very aggressive brain tumors 
with poor response to currently available therapies [214]. Wild-Bode and co-workers [208] 
described a rat orthotopic glioma model (L9 cells), with which they could demonstrate that 
sub-lethal doses of IR induced invasiveness of this brain tumor. We plan to employ this 
experimental model for an in vivo study with patupilone and IR. Pre-irradiated and highly 
invasive cells will be injected intracranially and rats will be treated with patupilone. As 
patupilone can cross the blood-brain barrier [217] and inhibit the IR-induced glioma cell 
invasion (as shown herein), we expect that brain tumors in patupilone-treated mice should be 
smaller, fewer satellites and have less invasive margins than tumors in untreated mice. These 
end-points and expression of TIMP proteins in tumor tissue after combined treatment could 
be estimated using histological techniques.
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